



## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2558	(544/328,333).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2006/06/12 14:09



chain nodes :

7 9 10 11

ring nodes :

1 2 3 4 5 6

chain bonds :

3-9 4-11 6-7 9-10

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 4-11 5-6 6-7 9-10

exact bonds :

3-9

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 9:CLASS 10:CLASS 11:Atom

Generic attributes :

7:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Number of Hetero Atoms : less than 2

Type of Ring System : Monocyclic

Element Count :

Node 7: Limited

C,C5



N,N1

O,O0

S,S0

=&gt;

Uploading C:\Program Files\Stnexp\Queries\10781075.str



chain nodes :

7 9 10 11

ring nodes :

1 2 3 4 5 6

chain bonds :

3-9 4-11 6-7 9-10

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 4-11 5-6 6-7 9-10

exact bonds :

3-9

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 9:CLASS 10:CLASS 11:Atom

Generic attributes :

7:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Number of Hetero Atoms : less than 2

Type of Ring System : Monocyclic

Element Count :

Node 7: Limited

C,C5

N,N1

O,O0


S,S0

L1 STRUCTURE UPLOADED

=&gt; d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 12:53:27 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 9794 TO ITERATE

20.4% PROCESSED 2000 ITERATIONS

4 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 189949 TO 201811

PROJECTED ANSWERS: 126 TO 656

L2 4 SEA SSS SAM L1

=> => s l1 sss ful

FULL SEARCH INITIATED 12:53:57 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 199561 TO ITERATE

100.0% PROCESSED 199561 ITERATIONS

597 ANSWERS

SEARCH TIME: 00.00.03

L3 597 SEA SSS FUL L1

=> => s l3

L4 31 L3

=> d l4 1-31 bib,ab,hitstr

L4 ANSWER 1 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2006:75171 CAPLUS  
 DN 144:150383  
 TI Preparation of N-(indazol-5-yl)-5-pyrimidinecarboxamides derivatives as  
 inhibitors of Rho-kinases  
 IN Sehon, Clark A.; Lee, Dennis; Goodman, Krista B.; Wang, Gren Z.; Viet,  
 Andrew Q.  
 PA SmithKline Beecham Corporation, USA  
 SO PCT Int. Appl., 72 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006009889	A1	20060126	WO 2005-US21559	20050617
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2004-580423P P 20040617

OS MARPAT 144:150383

AB Title compds. I [R8 = NH<sub>2</sub> and derivs., (un)substituted hetero/aryl, cycloalkyl, etc.; R9, R10 = independently absent, H, alkyl; R1 = cyclo/alkyl, (un)substituted alkyl/hetero/aryl; R2 = H, alkyl; R6 = H; R4, R5, R7 = independently H, halo, alkyl; and their pharmaceutically acceptable salts and solvates] were prepared as Rho-kinase, particularly ROCK1 kinase, inhibitors. Thus, reacting 4-(methyloxy)benzenecarboximidamide (preparation given) with 4-fluorobenzaldehyde and N-(1H-indazol-5-yl)-3-oxobutanamide in the presence of KOAc in DMSO at 100° for 3 h gave II in 32% yield. Most of the pyrimidines I were active inhibitors of ROCK1 kinase at concns. in the range of 10 µM to 0.8 µM. I are useful for treating hypertension, Alzheimer's disease, chronic and congestive heart failure and ischemic angina (no data).

IT **874118-88-4P**, 4-(4-Chloro-2-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-[2-(methyloxy)-4-pyridinyl]-1,4-dihydro-5-pyrimidinecarboxamide  
**874119-12-7P**, 4-(4-Fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-(2-pyridinyl)-1,4-dihydro-5-pyrimidinecarboxamide **874119-13-8P**,  
 4-(4-Fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-[6-(trifluoromethyl)-3-pyridinyl]-1,4-dihydro-5-pyrimidinecarboxamide **874119-16-1P**,  
 4-(4-Fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-(3-pyridinyl)-1,4-dihydro-5-pyrimidinecarboxamide **874119-20-7P**,  
 4-(4-Fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-(4-pyridinyl)-1,4-dihydro-5-pyrimidinecarboxamide **874119-21-8P**,  
 4-(4-Fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-(1-oxido-2-pyridinyl)-1,4-dihydro-5-pyrimidinecarboxamide **874119-28-5P**,  
 N-(1H-Indazol-5-yl)-4-methyl-2-(4-pyridinyl)-6-[4-(trifluoromethyl)phenyl]-1,6-dihydro-5-pyrimidinecarboxamide **874119-29-6P**,  
 N-(1H-Indazol-5-yl)-4-methyl-6-(5-phenyl-2-thienyl)-2-(4-pyridinyl)-1,6-dihydro-5-pyrimidinecarboxamide **874119-36-5P**,

4-(1,3-Benzodioxol-5-yl)-N-(1H-indazol-5-yl)-6-methyl-2-(4-pyridinyl)-1,4-dihydro-5-pyrimidinecarboxamide **874119-37-6P**,  
4-[2-Fluoro-4-(trifluoromethyl)phenyl]-N-(1H-indazol-5-yl)-6-methyl-2-(4-pyridinyl)-1,4-dihydro-5-pyrimidinecarboxamide **874119-38-7P**,  
4-(4-Chloro-2-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-(4-pyridinyl)-1,4-dihydro-5-pyrimidinecarboxamide **874119-49-0P**,  
4-(4-Chloro-2-fluorophenyl)-2-(2-chloro-4-pyridinyl)-N-(1H-indazol-5-yl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxamide **874119-50-3P**  
**874119-51-4P**, 2-(2-Chloro-4-pyridinyl)-4-[2-fluoro-4-(trifluoromethyl)phenyl]-N-(1H-indazol-5-yl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxamide **874119-56-9P**, 4-(4-Chloro-2-fluorophenyl)-2-(2-chloro-4-pyridinyl)-N-(6-fluoro-1H-indazol-5-yl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxamide **874119-57-0P**, 4-(4-Chloro-2-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-[6-(methyloxy)-3-pyridinyl]-1,4-dihydro-5-pyrimidinecarboxamide **874119-58-1P**,  
4-(4-Chloro-2-fluorophenyl)-2-(2,6-dichloro-4-pyridinyl)-N-(1H-indazol-5-yl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxamide **874119-60-5P**,  
4-(4-Chloro-2-fluorophenyl)-2-[2-[(4-chlorophenyl)oxy]-4-pyridinyl]-N-(1H-indazol-5-yl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxamide **874119-65-0P**, 2-(2-Chloro-4-pyridinyl)-4-(4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxamide **874119-66-1P**, 4-(1,3-Benzodioxol-5-yl)-2-(2-chloro-4-pyridinyl)-N-(1H-indazol-5-yl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxamide **874119-69-4P**, 2-(2-Chloro-4-pyridinyl)-4-cyclopropyl-N-(1H-indazol-5-yl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxamide **874119-75-2P**,  
4-(1,3-Benzodioxol-5-yl)-N-(6-fluoro-1H-indazol-5-yl)-6-methyl-2-[2-(methyloxy)-4-pyridinyl]-1,4-dihydro-5-pyrimidinecarboxamide **874119-76-3P** **874119-77-4P**, N-(6-Fluoro-1H-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl)phenyl]-6-methyl-2-[2-(methyloxy)-4-pyridinyl]-1,4-dihydro-5-pyrimidinecarboxamide **874119-78-5P**,  
4-(4-Chloro-2-fluorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-6-methyl-2-[2-(methyloxy)-4-pyridinyl]-1,4-dihydro-5-pyrimidinecarboxamide **874119-79-6P**, N-(6-Fluoro-1H-indazol-5-yl)-4-(4-fluorophenyl)-6-methyl-2-[2-(methyloxy)-4-pyridinyl]-1,4-dihydro-5-pyrimidinecarboxamide **874119-80-9P**, N-(6-Fluoro-1H-indazol-5-yl)-4-(4-fluorophenyl)-6-methyl-2-[6-(methyloxy)-3-pyridinyl]-1,4-dihydro-5-pyrimidinecarboxamide **874119-81-0P**, 4-(4-Chloro-2-fluorophenyl)-2-(2-chloro-4-pyridinyl)-N-(6-fluoro-1H-indazol-5-yl)-1,6-dimethyl-1,4-dihydro-5-pyrimidinecarboxamide **874119-82-1P**, 4-(1,3-Benzodioxol-5-yl)-N-(6-fluoro-1H-indazol-5-yl)-6-methyl-2-[6-(methyloxy)-3-pyridinyl]-1,4-dihydro-5-pyrimidinecarboxamide **874119-83-2P**  
**874119-84-3P**, N-(6-Fluoro-1H-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl)phenyl]-6-methyl-2-[6-(methyloxy)-3-pyridinyl]-1,4-dihydro-5-pyrimidinecarboxamide **874119-85-4P**,  
4-(4-Chloro-2-fluorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-6-methyl-2-[6-(methyloxy)-3-pyridinyl]-1,4-dihydro-5-pyrimidinecarboxamide **874119-86-5P**, 4-(4-Chlorophenyl)-2-(2-chloro-4-pyridinyl)-N-(6-fluoro-1H-indazol-5-yl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxamide **874119-87-6P**, 4-(4-Chlorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-6-methyl-2-[2-(methyloxy)-4-pyridinyl]-1,4-dihydro-5-pyrimidinecarboxamide **874119-88-7P**, 4-(4-Chlorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-6-methyl-2-[6-(methyloxy)-3-pyridinyl]-1,4-dihydro-5-pyrimidinecarboxamide **874119-89-8P**, N-(3-Chloro-6-fluoro-1H-indazol-5-yl)-4-(4-chloro-2-fluorophenyl)-2-(2-chloro-4-pyridinyl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxamide **874119-90-1P**, N-(3-Chloro-6-fluoro-1H-indazol-5-yl)-4-(4-chloro-2-fluorophenyl)-6-methyl-2-[2-(methyloxy)-4-pyridinyl]-1,4-dihydro-5-pyrimidinecarboxamide **874119-94-5P**,  
4-(4-Chlorophenyl)-2-[2-(ethyloxy)-4-pyridinyl]-N-(6-fluoro-1H-indazol-5-


yl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxamide **874119-95-6P**,  
 2-[2-(Ethyloxy)-4-pyridinyl]-N-(6-fluoro-1H-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl)phenyl]-6-methyl-1,4-dihydro-5-pyrimidinecarboxamide  
**874119-96-7P**, 4-(4-Chloro-2-fluorophenyl)-2-[2-(ethyloxy)-4-pyridinyl]-N-(6-fluoro-1H-indazol-5-yl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxamide **874119-97-8P**, 4-(4-Chlorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-6-methyl-2-(2-methyl-4-pyridinyl)-1,4-dihydro-5-pyrimidinecarboxamide **874119-98-9P**, N-(6-Fluoro-1H-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl)phenyl]-6-methyl-2-(2-methyl-4-pyridinyl)-1,4-dihydro-5-pyrimidinecarboxamide **874119-99-0P**,  
 4-(4-Chloro-2-fluorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-6-methyl-2-(2-methyl-4-pyridinyl)-1,4-dihydro-5-pyrimidinecarboxamide  
**874120-01-1P**, 4-(4-Chlorophenyl)-2-(2-chloro-4-pyridinyl)-6-methyl-N-(3-methyl-1H-indazol-5-yl)-1,4-dihydro-5-pyrimidinecarboxamide  
**874120-02-2P**, 4-(4-Chloro-2-fluorophenyl)-2-(2-chloro-4-pyridinyl)-6-methyl-N-(3-methyl-1H-indazol-5-yl)-1,4-dihydro-5-pyrimidinecarboxamide  
**874120-03-3P**, 2-(2-Chloro-4-pyridinyl)-4-[2-fluoro-4-(trifluoromethyl)phenyl]-6-methyl-N-(3-methyl-1H-indazol-5-yl)-1,4-dihydro-5-pyrimidinecarboxamide **874120-04-4P**, N-(3-Chloro-1H-indazol-5-yl)-4-(4-chlorophenyl)-2-(2-chloro-4-pyridinyl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxamide **874120-05-5P**, 4-(4-Chloro-2-fluorophenyl)-N-(3-chloro-1H-indazol-5-yl)-2-(2-chloro-4-pyridinyl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of indazolyl-pyrimidinecarboxamides derivs. as ROCK1 kinase inhibitors)


RN 874118-88-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-chloro-2-fluorophenyl)-1,4-dihydro-N-1H-indazol-5-yl-2-(2-methoxy-4-pyridinyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 874119-12-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-fluorophenyl)-1,4-dihydro-N-1H-indazol-5-yl-6-methyl-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 874119-13-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-fluorophenyl)-1,4-dihydro-N-1H-indazol-5-yl-6-methyl-2-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 874119-16-1 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(4-fluorophenyl)-1,4-dihydro-N-1H-indazol-5-yl-6-methyl-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 874119-20-7 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(4-fluorophenyl)-1,4-dihydro-N-1H-indazol-5-yl-6-methyl-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)






RN 874119-21-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-fluorophenyl)-1,4-dihydro-N-1H-indazol-5-yl-6-methyl-2-(1-oxido-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 874119-28-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,4-dihydro-N-1H-indazol-5-yl-6-methyl-2-(4-pyridinyl)-4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 874119-29-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 1,4-dihydro-N-1H-indazol-5-yl-6-methyl-4-(5-phenyl-2-thienyl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 874119-36-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(1,3-benzodioxol-5-yl)-1,4-dihydro-N-1H-indazol-5-yl-6-methyl-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 874119-37-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[2-fluoro-4-(trifluoromethyl)phenyl]-1,4-dihydro-N-1H-indazol-5-yl-6-methyl-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 874119-38-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-chloro-2-fluorophenyl)-1,4-dihydro-N-1H-indazol-5-yl-6-methyl-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 874119-49-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-chloro-2-fluorophenyl)-2-(2-chloro-4-pyridinyl)-1,4-dihydro-N-1H-indazol-5-yl-6-methyl- (9CI) (CA INDEX NAME)




RN 874119-50-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-(2-chloro-4-pyridinyl)-1,4-dihydro-N-1H-indazol-5-yl-6-methyl-4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 874119-51-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-(2-chloro-4-pyridinyl)-4-[2-fluoro-4-(trifluoromethyl)phenyl]-1,4-dihydro-N-1H-indazol-5-yl-6-methyl- (9CI) (CA INDEX NAME)




RN 874119-56-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-chloro-2-fluorophenyl)-2-(2-chloro-4-pyridinyl)-N-(6-fluoro-1H-indazol-5-yl)-1,4-dihydro-6-methyl- (9CI) (CA INDEX NAME)




RN 874119-57-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-chloro-2-fluorophenyl)-1,4-dihydro-N-1H-indazol-5-yl-2-(6-methoxy-3-pyridinyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 874119-58-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-chloro-2-fluorophenyl)-2-(2,6-dichloro-4-pyridinyl)-1,4-dihydro-N-1H-indazol-5-yl-6-methyl- (9CI) (CA INDEX NAME)




RN 874119-60-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-chloro-2-fluorophenyl)-2-[2-(4-chlorophenoxy)-4-pyridinyl]-1,4-dihydro-N-1H-indazol-5-yl-6-methyl- (9CI)  
(CA INDEX NAME)




RN 874119-65-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-(2-chloro-4-pyridinyl)-4-(4-fluorophenyl)-1,4-dihydro-N-1H-indazol-5-yl-6-methyl- (9CI) (CA INDEX NAME)




RN 874119-66-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(1,3-benzodioxol-5-yl)-2-(2-chloro-4-pyridinyl)-1,4-dihydro-N-1H-indazol-5-yl-6-methyl- (9CI) (CA INDEX NAME)




RN 874119-69-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-(2-chloro-4-pyridinyl)-4-cyclopropyl-1,4-dihydro-N-1H-indazol-5-yl-6-methyl- (9CI) (CA INDEX NAME)




RN 874119-75-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(1,3-benzodioxol-5-yl)-N-(6-fluoro-1H-indazol-5-yl)-1,4-dihydro-2-(2-methoxy-4-pyridinyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 874119-76-3 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(6-fluoro-1H-indazol-5-yl)-1,4-dihydro-2-(2-methoxy-4-pyridinyl)-6-methyl-4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 874119-77-4 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(6-fluoro-1H-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl)phenyl]-1,4-dihydro-2-(2-methoxy-4-pyridinyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 874119-78-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-chloro-2-fluorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-1,4-dihydro-2-(2-methoxy-4-pyridinyl)-6-methyl- (9CI) (CA INDEX NAME)



RN 874119-79-6 CAPLUS


CN 5-Pyrimidinecarboxamide, N-(6-fluoro-1H-indazol-5-yl)-4-(4-fluorophenyl)-1,4-dihydro-2-(2-methoxy-4-pyridinyl)-6-methyl- (9CI) (CA INDEX NAME)



RN 874119-80-9 CAPLUS


CN 5-Pyrimidinecarboxamide, N-(6-fluoro-1H-indazol-5-yl)-4-(4-fluorophenyl)-

1,4-dihydro-2-(6-methoxy-3-pyridinyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 874119-81-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-chloro-2-fluorophenyl)-2-(2-chloro-4-pyridinyl)-N-(6-fluoro-1H-indazol-5-yl)-1,4-dihydro-1,6-dimethyl- (9CI) (CA INDEX NAME)



RN 874119-82-1 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(1,3-benzodioxol-5-yl)-N-(6-fluoro-1H-indazol-5-yl)-1,4-dihydro-2-(6-methoxy-3-pyridinyl)-6-methyl- (9CI) (CA INDEX NAME)



RN 874119-83-2 CAPLUS


CN 5-Pyrimidinecarboxamide, N-(6-fluoro-1H-indazol-5-yl)-1,4-dihydro-2-(6-methoxy-3-pyridinyl)-6-methyl-4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)






RN 874119-84-3 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(6-fluoro-1H-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl)phenyl]-1,4-dihydro-2-(6-methoxy-3-pyridinyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 874119-85-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-chloro-2-fluorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-1,4-dihydro-2-(6-methoxy-3-pyridinyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 874119-86-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-chlorophenyl)-2-(2-chloro-4-pyridinyl)-N-(6-fluoro-1H-indazol-5-yl)-1,4-dihydro-6-methyl- (9CI) (CA INDEX NAME)




RN 874119-87-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-chlorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-1,4-dihydro-2-(2-methoxy-4-pyridinyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 874119-88-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-chlorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-1,4-dihydro-2-(6-methoxy-3-pyridinyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 874119-89-8 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(3-chloro-6-fluoro-1H-indazol-5-yl)-4-(4-chloro-2-fluorophenyl)-2-(2-chloro-4-pyridinyl)-1,4-dihydro-6-methyl- (9CI) (CA INDEX NAME)




RN 874119-90-1 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(3-chloro-6-fluoro-1H-indazol-5-yl)-4-(4-chloro-2-fluorophenyl)-1,4-dihydro-2-(2-methoxy-4-pyridinyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 874119-94-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-chlorophenyl)-2-(2-ethoxy-4-pyridinyl)-N-(6-fluoro-1H-indazol-5-yl)-1,4-dihydro-6-methyl- (9CI) (CA INDEX NAME)




RN 874119-95-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-(2-ethoxy-4-pyridinyl)-N-(6-fluoro-1H-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl)phenyl]-1,4-dihydro-6-methyl- (9CI) (CA INDEX NAME)




RN 874119-96-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-chloro-2-fluorophenyl)-2-(2-ethoxy-4-pyridinyl)-N-(6-fluoro-1H-indazol-5-yl)-1,4-dihydro-6-methyl- (9CI) (CA INDEX NAME)




RN 874119-97-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-chlorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-1,4-dihydro-6-methyl-2-(2-methyl-4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 874119-98-9 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(6-fluoro-1H-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl)phenyl]-1,4-dihydro-6-methyl-2-(2-methyl-4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 874119-99-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-chloro-2-fluorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-1,4-dihydro-6-methyl-2-(2-methyl-4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 874120-01-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-chlorophenyl)-2-(2-chloro-4-pyridinyl)-1,4-dihydro-6-methyl-N-(3-methyl-1H-indazol-5-yl)- (9CI) (CA INDEX NAME)




RN 874120-02-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-chloro-2-fluorophenyl)-2-(2-chloro-4-pyridinyl)-1,4-dihydro-6-methyl-N-(3-methyl-1H-indazol-5-yl)- (9CI) (CA INDEX NAME)




RN 874120-03-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-(2-chloro-4-pyridinyl)-4-[2-fluoro-4-(trifluoromethyl)phenyl]-1,4-dihydro-6-methyl-N-(3-methyl-1H-indazol-5-yl)- (9CI) (CA INDEX NAME)




RN 874120-04-4 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(3-chloro-1H-indazol-5-yl)-4-(4-chlorophenyl)-2-(2-chloro-4-pyridinyl)-1,4-dihydro-6-methyl- (9CI) (CA INDEX NAME)




RN 874120-05-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-chloro-2-fluorophenyl)-N-(3-chloro-1H-indazol-5-yl)-2-(2-chloro-4-pyridinyl)-1,4-dihydro-6-methyl- (9CI) (CA INDEX NAME)



RE.CNT 1      THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2005:549539 CAPLUS  
 DN 143:188635  
 TI A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly  
 AU Stray, Stephen J.; Bourne, Christina R.; Punna, Sreenivas; Lewis, Warren G.; Finn, M. G.; Zlotnick, Adam  
 CS Department of Biochemistry and Molecular Biology BRC 464, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73190, USA  
 SO Proceedings of the National Academy of Sciences of the United States of America (2005), 102(23), 8138-8143  
 CODEN: PNASA6; ISSN: 0027-8424  
 PB National Academy of Sciences  
 DT Journal  
 LA English  
 AB Heteroaryldihydropyrimidines (HAPs) are a new class of antivirals inhibiting production of hepatitis B virus (HBV) virions in tissue culture. Here, we examine the effect of a representative HAP mol., Me 4-(2-chloro-4-fluorophenyl)-6-methyl-2-(pyridin-2-yl)-1,4-dihydropyrimidine-5-carboxylate (HAP-1), on the in vitro assembly of HBV capsid protein (Cp). HAP-1 enhances the rate and extent of Cp assembly over a broad concentration range. Aberrant particles, dominated by hexagonal arrays of Cp, were observed from assembly reactions with high HAP-1 concns. HAP-1 also led to dissociation of metastable HBV capsids, overcoming a kinetic barrier to dissociation by scavenging Cp and redirecting its assembly into hexamer-rich structures. Thus, HAP drugs act as allosteric effectors that induce an assembly-active state and, at high concentration, preferentially stabilize noncapsid polymers of Cp. HAP compds. may have multiple effects in vivo stemming from inappropriate assembly of Cp. These results show that activating and deregulating virus assembly may be a powerful general approach for antiviral therapeutics.  
 IT **862097-09-4**  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly)  
 RN 862097-09-4 CAPLUS  
 CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT



L4 ANSWER 3 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:29315 CAPLUS

DN 142:114092

TI Preparation of pyrimidines as modulators of voltage-gated ion channels

IN Wilson, Dean Mitchell; Martinborough, Esther; Neubert, Timothy Donald; Termin, Andreas Peter; Gonzales, Jesus E., III; Zimmermann, Nicole

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 195 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005003099	A2	20050113	WO 2004-US21440	20040702
	WO 2005003099	A3	20050512		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				
	AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				
	EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,				
	SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,				
	SN, TD, TG				
	AU 2004253962	A1	20050113	AU 2004-253962	20040702
	CA 2531061	AA	20050113	CA 2004-2531061	20040702
	US 2005049247	A1	20050303	US 2004-884865	20040702
	EP 1638955	A2	20060329	EP 2004-777512	20040702
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI	US 2003-484362P	P	20030702		
	US 2003-500200P	P	20030904		
	WO 2004-US21440	W	20040702		

OS MARPAT 142:114092

AB The title compds. [I; R5 = COR3, CO2R3, or R5'; R5' = CONH2 and derivs., SO2H and derivs., CON(CN)H and derivs., etc.; R1, R2 = independently H, (un)substituted aliphatic, 5-6-membered aryl ring containing 0-5 heteroatoms,

or  
a 3-7-membered saturated or partially unsatd. ring containing 0-3 heteroatoms;

or  
R1NR2 = (un)substituted 3-8-membered heterocyclyl or heteroaryl containing 1-3 heteroatoms; A = (un)substituted 5-6-membered aryl ring, or 8-10-membered bicyclic aryl ring containing 0-5 heteroatoms, or a 3-7-membered saturated or partially unsatd. ring containing 0-3 heteroatoms; R4 = Q-Rx; Q = a bond, alkylidene chain wherein up to two non-adjacent methylene units of Q are optionally replaced by CO, CO2, COCO, CONH and derivs., SO, SO2, O, S, NH and derivs., etc. with proviso; and their pharmaceutically acceptable salts], useful as inhibitors of voltage-gated sodium channels and calcium channels, were prepared. Thus, Pd-cross coupling of 5-ethoxycarbonyl-2-chloro-4-(N,N-dimethylamino)pyrimidine (preparation given) with phenylboronic acid gave II in 92% yield. Representative compds. I were found to possess desired N-type calcium channel modulation activity and selectivity (no specific data given). Also, representative compds. I were found to possess desired voltage gated sodium channel activity and selectivity (no specific data given). The invention also provides pharmaceutically

acceptable compns. comprising the compds. I and methods of using the compns. in the treatment of various disorders.

IT **823792-47-8P 823792-81-0P 823792-84-3P**

**823793-09-5P 823793-34-6P 823794-30-5P**


**823794-63-4P 823795-01-3P 823795-32-0P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidines as modulators of voltage-gated ion channels)


RN 823792-47-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-methyl-1-piperazinyl)-2-(4-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 823792-81-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(1-piperidinyl)-2-(4-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 823792-84-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-(4-pyridinyl)-4-(1-pyrrolidinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 823793-09-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-methyl-1-piperazinyl)-2-(3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 823793-34-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(1-piperidinyl)-2-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 823794-30-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-(3-pyridinyl)-4-(1-pyrrolidinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 823794-63-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-(2-pyridinyl)-4-(1-pyrrolidinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 823795-01-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-methyl-1-piperazinyl)-2-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 823795-32-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(1-piperidinyl)-2-(3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)

10/781,075



L4 ANSWER 4 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2003:947710 CAPLUS  
 DN 140:4777

TI Methods of preparation of solid phase bound dialkylaminopropenoate and  
 dialkylaminopropenone intermediates useful in the microwave-assisted  
 synthesis of heterocycles

IN Westman, Jacob; Lundin, Ronny

PA Personal Chemistry I Uppsala AB, Swed.

SO Eur. Pat. Appl., 17 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1367045	A1	20031203	EP 2002-445069	20020531
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	CA 2487659	AA	20031211	CA 2003-2487659	20030522
	WO 2003101933	A1	20031211	WO 2003-SE827	20030522
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU	2003228199	A1	20031219	AU 2003-228199	20030522
EP	1509491	A1	20050302	EP 2003-725965	20030522
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
JP	2005528437	T2	20050922	JP 2004-509627	20030522
US	2004005637	A1	20040108	US 2003-448060	20030530
US	7019094	B2	20060328		
US	2006041095	A1	20060223	US 2005-244097	20051006
PRAI	EP 2002-445069	A	20020531		
	US 2002-384133P	P	20020531		
	WO 2003-SE827	W	20030522		
	US 2003-448060	A3	20030530		

OS CASREACT 140:4777; MARPAT 140:4777

AB Novel solid-supported intermediate products I [wherein (a) when coupled to the polymeric support through R1, the R-groups are defined as follows: R1 = independently (cyclo)alkyl, heterocyclyl, or benzyl; or N(R1)2 = heterocyclyl; R2 = H or alkyl; R4 = (un)substituted (hetero)aryl or OR5; when R4 = (un)substituted (hetero)aryl, then R3 = H, alkyl, (un)substituted (hetero)aryl, or CO2R5; when R4 = OR5, then R3 = CN, CO2R5, NHCOR5, NHCO2R5, or COR5; R5 = independently H, alkyl, benzyl, or (un)substituted (hetero)aryl; or (b) when coupled to the polymeric support through R4, the R-groups are defined as follows: R1 and R2 = as above; R3 = as above except CO2R5 and COR5; R4 = OR5; R5 = as above], which are suitable for synthesis of heterocyclic compds., are disclosed. Methods for preparing I, as well as their use in simple and fast methods on solid phase for microwave-assisted synthesis of heterocycles, are also disclosed. The solid phase technique allows for easy automation and eliminates time-consuming purification steps, and microwave-assisted heating

shortens reaction times substantially. Heterocyclic compds. may be produced in high yield with high purity using these methods. For example, Merrifield resin was swelled in DMF, N-benzoylglycine loaded in the presence of Cs<sub>2</sub>CO<sub>3</sub>, and the reaction mixture heated at 200° for 10 min to give the coupled product (80%). The solid-supported N-benzoylglycine benzyl ester was heated with DMF di-Et acetal at 180° for 10 min to afford the resin-bound dimethylaminopropenoate (no data). Exposure of the resin-bound dimethylaminopropenoate and 5,5-dimethyl-1,3-cyclohexanedione in AcOH to microwave heating at 180° for 10 min provided 3-(benzoylamino)-5-oxo-5,6,7,8-tetrahydro-2H-1-benzopyran-2-one (95% yield, 98% purity).


IT **103294-37-7P**, Ethyl 2-(4-pyridyl)-4-(4-nitrophenyl)pyrimidine-5-carboxylate

RL: IMF (Industrial manufacture); PREP (Preparation)

(preparation of Merrifield resin-bound dialkylaminopropenoate and dialkylaminopropenone intermediates useful in microwave-assisted synthesis of heterocycles)

RN 103294-37-7 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-nitrophenyl)-2-(4-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2003:92030 CAPLUS  
 DN 139:62661  
 TI Inhibition of Hepatitis B Virus Replication by Drug-Induced Depletion of Nucleocapsids  
 AU Deres, Karl; Schroeder, Claus H.; Paessens, Arnold; Goldmann, Siegfried; Hacker, Hans Joerg; Weber, Olaf; Kraemer, Thomas; Niewoehner, Ulrich; Pleiss, Ulrich; Stoltefuss, Juergen; Graef, Erwin; Koletzki, Diana; Masantschek, Ralf N. A.; Reimann, Anja; Jaeger, Rainer; Gro, Rainer; Beckermann, Bernhard; Schlemmer, Karl-Heinz; Haebich, Dieter; Ruebsamen-Waigmann, Helga  
 CS Dep. Virology, Bayer Res. Center, Wuppertal, Germany  
 SO Science (Washington, DC, United States) (2003), 299(5608), 893-896  
 CODEN: SCIEAS; ISSN: 0036-8075  
 PB American Association for the Advancement of Science  
 DT Journal  
 LA English  
 AB Chronic hepatitis B virus (HBV) infection is a major cause of liver disease. Only interferon- $\alpha$  and the nucleosidic inhibitors of the viral polymerase, 3TC and adefovir, are approved for therapy. However, these therapies are limited by the side effects of interferon and the substantial resistance of the virus to nucleosidic inhibitors. Potent new antiviral compds. suitable for monotherapy or combination therapy are highly desired. We describe non-nucleosidic inhibitors of HBV nucleocapsid maturation that possess in vitro and in vivo antiviral activity. These inhibitors have potential for future therapeutic regimens to combat chronic HBV infection.  
 IT **246872-58-2**, Bay 38-7690 **298708-81-3**, Bay 41-4109  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids)  
 RN 246872-58-2 CAPLUS  
 CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 298708-81-3 CAPLUS  
 CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester, (4R)- (9CI) (CA INDEX



10/781,075

NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2002:906192 CAPLUS  
 DN 138:4607  
 TI Method for resolution of the enantiomers of methyl 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxylate racemate using (-)-camphanic acid  
 IN Goldmann, Siegfried; Fey, Peter  
 PA Bayer Aktiengesellschaft, Germany  
 SO PCT Int. Appl., 10 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA German  
 FAN.CNT 1

*Common AES.*

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002094807	A1	20021128	WO 2002-EP5339	20020515
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10125131	A1	20021205	DE 2001-10125131	20010523
EP 1395573	A1	20040310	EP 2002-740603	20020515
EP 1395573	B1	20050921		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, EI, RO, MK, CY, AL, TR				
CN 1531532	A	20040922	CN 2002-810454	20020515
ES 2249591	T3	20060401	ES 2002-2740603	20020515
US 2004242878	A1	20041202	US 2004-478602	20040715
US 6987185	B2	20060117		
PRAI DE 2001-10125131	A	20010523		
WO 2002-EP5339	W	20020515		

*no ODP*

AB The enantiomers of Me 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxylate can be separated with the aid of (-)-camphanic acid followed by neutralization of the diastereomeric salt with a weak base (e.g., sodium carbonate).

IT **298708-81-3P**


RL: PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)

(method for resolution of racemic Me 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxylate using (-)-camphanic acid)

RN 298708-81-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT **298708-79-9**

RL: RCT (Reactant); RACT (Reactant or reagent)

(method for resolution of racemic Me 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxylate using (-)-camphanic acid)

RN 298708-79-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



IT **476617-50-2P 476617-52-4P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(method for resolution of racemic Me 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxylate using (-)-camphanic acid)

RN 476617-50-2 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester, (4R)-, mono[(1S,4R)-4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxylate] (9CI) (CA INDEX NAME)

CM 1

10/781,075

CRN 298708-81-3  
CMF C18 H13 Cl F3 N3 O2


Absolute stereochemistry. Rotation (-).



CM 2

CRN 13429-83-9  
CMF C10 H14 O4

Absolute stereochemistry. Rotation (-).




RN 476617-52-4 CAPLUS  
CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester, (4S)-, mono[(1S,4R)-4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxylate] (9CI) (CA INDEX NAME)

CM 1

CRN 476617-51-3  
CMF C18 H13 Cl F3 N3 O2

Absolute stereochemistry.




CM 2

CRN 13429-83-9

CMF C10 H14 O4

Absolute stereochemistry. Rotation (-).



RE.CNT 1      THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:868695 CAPLUS

DN 137:352786

TI Preparation of substituted N'-(arylcarbonyl)benzhydrazides and N'-(benzylidene)benzhydrazides and analogs as activators of caspases and inducers of apoptosis for use as antitumor agents

IN Cai, Sui Xiong; Kasibhatla, Shailaja; Drewe, John; Reddy, P. Sanjeeva; Zhang, Han-Zhong

PA Cytovia, Inc., USA

SO PCT Int. Appl., 80 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002089745	A2	20021114	WO 2002-US14722	20020510
	WO 2002089745	A3	20030227		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2003013743	A1	20030116	US 2002-141769	20020510
	US 6716859	B2	20040406		
	EP 1392219	A2	20040303	EP 2002-731739	20020510
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	US 2004186078	A1	20040923	US 2004-816893	20040405
PRAI	US 2001-289803P	P	20010510		
	US 2002-141769	A3	20020510		
	WO 2002-US14722	W	20020510		


OS MARPAT 137:352786

AB The present invention is directed to substituted N'-(arylcarbonyl)benzhydrazides, N'-(arylcarbonyl)benzylidene hydrazides and analogs thereof, represented by Ar1C(O)NR2NR1C(O)Ar2 and Ar1C(O)NR2N:CR1Ar2 (e.g. N'-(2-phenoxy pyridine-3-carbonyl)-3-(trifluoromethyl)benzhydrazide (1)): wherein Ar1 is optionally substituted pyridyl, pyrimidinyl or phenyl; Ar2 is optionally substituted aryl or heteroaryl; and R1 and R2 are independently H, alkyl or cycloalkyl; with the proviso that said compound is other than 4-hydroxybenzoic acid (2-hydroxybenzylidene)hydrazide. The present invention also relates to the discovery that these compds. are activators of caspases and inducers of apoptosis and therefore may be used to induce cell death in a variety of clin. conditions in which uncontrolled growth and spread of abnormal cells occurs. Although the methods of preparation are not claimed, 42 example preps. are included. Compound 1 and analogs were identified as caspase cascade activators and inducers of apoptosis in solid tumor cells and as antineoplastic compound that inhibits cell proliferation (GI50). Treatment with 1 leads to cell cycle arrest and apoptosis in T-47D cells. Compound 1 and analogs were identified as antineoplastic compound that selectively inhibits the proliferation of breast cancer cells (GI50). Compound 1 was also found to inhibit the clonogenic survival of T47D and MX-1 solid tumor cell lines.


IT **474973-54-1P**, 4-(Pyridin-4-yl)-2-(pyridin-2-yl)pyrimidine-5-carboxylic acid (3-trifluoromethylbenzylidene)hydrazide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of substituted N'-(arylcarbonyl)benzhydrazides and N'-(benzylidene)benzhydrazides and analogs as activators of caspases and inducers of apoptosis for use as antitumor agents)  
 RN 474973-54-1 CAPLUS  
 CN 5-Pyrimidinecarboxylic acid, 2-(2-pyridinyl)-4-(4-pyridinyl)-, [[3-(trifluoromethyl)phenyl]methylene]hydrazide (9CI) (CA INDEX NAME)



IT **400077-54-5**, 4-(Pyridin-4-yl)-2-(pyridin-2-yl)pyrimidine-5-carboxylic acid hydrazide  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of substituted N'-(arylcarbonyl)benzhydrazides and N'-(benzylidene)benzhydrazides and analogs as activators of caspases and inducers of apoptosis for use as antitumor agents)  
 RN 400077-54-5 CAPLUS  
 CN 5-Pyrimidinecarboxylic acid, 2-(2-pyridinyl)-4-(4-pyridinyl)-, hydrazide (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2002:846120 CAPLUS  
 DN 138:271628  
 TI Alkylaminopropenones and alkylamino-propenoates as efficient and versatile  
 synthons in microwave-assisted combinatorial synthesis  
 AU Westman, J.; Lundin, R.; Stalberg, J.; Ostbye, M.; Franzen, A.;  
 Hurynowicz, A.  
 CS Personal Chemistry AB, Uppsala, 753 18, Swed.  
 SO Combinatorial Chemistry and High Throughput Screening (2002), 5(7),  
 565-570  
 CODEN: CCHSFU; ISSN: 1386-2073  
 PB Bentham Science Publishers  
 DT Journal  
 LA English  
 OS CASREACT 138:271628  
 AB A simple and fast one-pot method using microwave irradiation for the synthesis  
 of a number of small libraries of diverse heterocycles is described in this  
 paper. The two-step one-pot method includes the formation of  
 alkylaminopropenones or alkylaminopropenoates (using 1,1-diethoxy-N,N-  
 dimethylmethanamine) in 5 min at 180°C and a subsequent treatment  
 with dinucleophiles for 3 to 5 min at 150°C to 180°C to form  
 a variety of biol. interesting heterocycles in a cascade-type reaction.  
 The combination of combinatorial chemical and microwave-assisted synthesis  
 was found to be very efficient.  
 IT **503175-53-9P**  
 RL: CPN (Combinatorial preparation); SPN (Synthetic preparation); CMBI  
 (Combinatorial study); PREP (Preparation)  
 ((alkylamino)propenones and (alkylamino)propenoates as efficient and  
 versatile synthons in microwave-assisted combinatorial synthesis)  
 RN 503175-53-9 CAPLUS  
 CN 5-Pyrimidinecarboxylic acid, 4-phenyl-2-(4-pyridinyl)-, ethyl ester (9CI)  
 (CA INDEX NAME)




RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT



L4 ANSWER 9 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2002:300226 CAPLUS  
 DN 138:107  
 TI Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model  
 AU Weber, O.; Schlemmer, K.-H.; Hartmann, E.; Hagelschuer, Ina; Paessens, A.; Graef, E.; Deres, K.; Goldmann, S.; Niewoehner, U.; Stoltefuss, J.; Haebich, D.; Ruebsamen-Waigmann, H.; Wohlfeil, Stefan  
 CS Department of Antiinfective Research, Bayer AG Pharmaceutical Research Centre, Wuppertal, D-42096, Germany  
 SO Antiviral Research (2002), 54(2), 69-78  
 CODEN: ARSRDR; ISSN: 0166-3542  
 PB Elsevier Science B.V.  
 DT Journal  
 LA English  
 AB BAY 41-4109 is a member of a class of heteroaryl-pyrimidines that was recently identified as potent inhibitors of human hepatitis B virus (HBV) replication. We have investigated the antiviral activity of BAY 41-4109 (Me (R)-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-methyl-1,4-dihydro-pyrimidine-5-carboxylate) in HBV-transgenic mice (Tg [HBV1.3 fsX-3'5']). Bay 41-4109 was administered per os using different schedules (b.i.d. or t.i.d. for up to 28 days) and dosages ranging from 3 to 30 mg/kg. The compound reduced viral DNA in the liver and in the plasma dose-dependently with efficacy comparable to 3TC. In contrast to 3TC-treated mice, we found a reduction of cytoplasmic hepatitis B virus core antigen (HBcAg) in liver sections of BAY 41-4109-treated mice, which indicated a different mode of action. Pharmacokinetic studies in mice have shown rapid absorption, a bioavailability of 30% and dose-proportional plasma concns. We conclude that BAY 41-4109 is a new anti-HBV drug candidate.  
 IT **298708-81-3**, BAY 41-4109  
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (inhibition of human hepatitis B virus by BAY 41-4109)  
 RN 298708-81-3 CAPLUS  
 CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:220565 CAPLUS

DN 136:247604

TI Preparation of pyrimidine and pyridine derivatives as N-type calcium channel inhibitors and analgesics

IN Ohno, Seiji; Otani, Kayo; Niwa, Seiji; Iwayama, Satoshi; Takahara, Akira; Koganei, Hajime; Ono, Yukitsugu; Fujita, Shinichi; Takeda, Tomoko; Hagiwara, Masako; Okajima, Akiko

PA Ajinomoto Co., Inc., Japan

SO PCT Int. Appl., 207 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002022588	A1	20020321	WO 2001-JP7841	20010910
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001084504	A5	20020326	AU 2001-84504	20010910
	EP 1318147	A1	20030611	EP 2001-963562	20010910
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2004009991	A1	20040115	US 2003-387543	20030314
PRAI	JP 2000-280438	A	20000914		
	JP 2001-126832	A	20010425		
	WO 2001-JP7841	W	20010910		

OS MARPAT 136:247604

AB The title compds., e.g. I [A = 1-naphthyl, pyridin-3-yl, etc.; C = alkyl, etc.; E = alkyl, etc.; F = thiophen-3-yl, etc.; X1 = NR14, etc.; R14 = H, etc.; Y = (un)saturated hydrocarbon moiety, etc.], are prepared I are useful as

therapeutic agents for pain and for various diseases in which N-type calcium channels participate. In rats dosed orally with 4-(2,4-dimethylphenyl)-6-methyl-2-(methylthio)-N-(3-phenylpropyl)-5-pyrimidinecarboxamide at 3 mg/kg, the flinching behavior frequency was 39±11 times/60 min vs. 116±8 times/60 min in controls.

IT 404568-22-5P 404568-24-7P 404568-33-8P

404568-38-3P 404568-40-7P 404568-43-0P

404568-47-4P 404568-56-5P 404568-57-6P

404568-65-6P 404568-69-0P 404568-73-6P


404568-78-1P 404568-83-8P 404568-84-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine and pyridine derivs. as N-type calcium channel inhibitors and analgesics)


RN 404568-22-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3-chlorophenyl)-6-methyl-N-(3-phenyl-2-propenyl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404568-24-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3-chlorophenyl)-N-(3,3-diphenylpropyl)-6-methyl-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404568-33-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3-chlorophenyl)-6-methyl-N-(3-phenylpropyl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404568-38-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,4-dichlorophenyl)-6-methyl-N-(3-phenylpropyl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404568-40-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-6-methyl-N-(3-phenylpropyl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404568-43-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,4-dichlorophenyl)-6-methyl-N-(4-phenylbutyl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404568-47-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,4-dichlorophenyl)-6-methyl-N-(2-phenylethyl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404568-56-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-methoxyphenyl)-6-methyl-N-(3-phenylpropyl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404568-57-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-methyl-N-(3-phenylpropyl)-2,6-di-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 404568-65-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-methyl-6-(3-nitrophenyl)-N-(3-phenylpropyl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404568-69-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-methyl-6-(3-methylphenyl)-N-(3-phenylpropyl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404568-73-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3-fluorophenyl)-6-methyl-N-(3-phenylpropyl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404568-78-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3-methoxyphenyl)-6-methyl-N-(3-phenylpropyl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404568-83-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-6-methyl-N-(3-phenylpropyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 404568-84-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-6-methyl-N-(3-phenylpropyl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:185105 CAPLUS

DN 136:247491

TI Medicaments against viral infections containing chromanones in combination with other virucidal compounds

IN Nikolic, Susanne; Bartel, Stephan; Brands, Michael; Niewoehner, Ulrich; Paessens, Arnold; Graef, Erwin; Schlemmer, Karl-Heinz; Henninger, Kerstin; Endermann, Rainer; Weber, Olaf; Koletzki, Diana

PA Bayer Aktiengesellschaft, Germany

SO PCT Int. Appl., 165 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002020509	A2	20020314	WO 2001-EP9772	20010824
	WO 2002020509	A3	20020627		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10043791	A1	20020314	DE 2000-10043791	20000906
	DE 10054932	A1	20020508	DE 2000-10054932	20001106
	AU 2001089831	A5	20020322	AU 2001-89831	20010824
	US 2002082264	A1	20020627	US 2001-943046	20010830
PRAI	DE 2000-10043791	A	20000906		
	DE 2000-10054932	A	20001106		
	WO 2001-EP9772	W	20010824		

OS MARPAT 136:247491

AB Chromanones I [R1 = Br, (un)substituted Ph, pyrrolyl, pyridyl, pyrimidinyl, piperazinyl, quinolyl; R2 = H; R1R2 = CH:CHCH:CH; R3, R4 = (un)substituted alkyl; R3R4 = (un)substituted alkylene, oxaalkylene, azaalkylene; R5 = (un)substituted alkyl; R6 = H, (un)substituted alkyl; R7 = H, R8 = OH; R7R8 = O] were prepared for use as virucides. I in combination with HBV polymerase inhibitors, HBV-DNA- or HBV-core protein inhibitors and/or isoxazoles and optionally interferon inhibit the multiplication of the HBV virus in an improved manner (no data). Thus, 3-BrC6H4OH was acetylated, subjected to Claisen rearrangement to give 4,2-Br(HO)C6H3COMe, which was cyclized with cyclohexanone to give I [R1, R5, R6 = H, R2 = 7-Br, R3R4 = (CH2)5, R7R8 = O]. This compound was treated with acrylonitrile to give the 3-(2-cyanoethyl) derivative which was arylated with 3-MeC6H4B(OH)2 to give I [R1 = R6 = H, R2 = 7-(2-MeC6H4), R3R4 = (CH2)5, R5 = CH2CH2CN, R7R8 = O]. This compound had an IC50 for inhibition of hepatitis B virus of < 0.12 µM. Some of the isoxazoles that are used in combination with I are also prepared

IT 298708-81-3 298708-83-5

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(virucides against hepatitis B virus containing chromanones and isoxazoles)

RN 298708-81-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester, (4R)- (9CI) (CA INDEX NAME)




Absolute stereochemistry. Rotation (-).



RN 298708-83-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L4 ANSWER 12 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:693321 CAPLUS

DN 135:242247

TI Preparation of 2-heterocyclyl-4-phenyldihydropyrimidines as antiviral agents for treatment of hepatitis B infection

IN Niewoehner, Ulrich; Stoltefuss, Juergen; Goldmann, Siegfried; Kraemer, Thomas; Schlemmer, Karl-Heinz; Keldenich, Joerg; Paessens, Arnold; Graef, Erwin; Weber, Olaf; Deres, Karl

PA Bayer Aktiengesellschaft, Germany

SO PCT Int. Appl., 96 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001068647	A1	20010920	WO 2001-EP2445	20010305
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 10012549	A1	20010920	DE 2000-10012549	20000315
PRAI	DE 2000-10012549	A	20000315		

OS MARPAT 135:242247

AB Title compds. [I and II; R1-R3 = H, halo, cyano, alkyl, alkoxy, NO<sub>2</sub>; R4 = (substituted) (O-, S-, NR7-interrupted) alkyl; R7 = H, alkyl; R5 = (substituted) pyridyl, thiazolyl, oxazolyl, furyl, thienyl; R6 = (substituted) heterocyclyl], were prepared Thus, 4-(2-chloro-4-fluorophenyl)-2-(thiazol-2-yl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxylic acid hydrazide (preparation given) and Et acetimidate hydrochloride were refluxed with pyridine for 4 h to give 93.8% 4-(2-chloro-4-fluorophenyl)-6-methyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine. Several I reduced intra- and/or extracellular hepatitis B viral DNA in virus-producing Hep G2.2.15 cells with IC<sub>50</sub> = 100-200 nM.

IT 361161-74-2P 361161-75-3P 361161-77-5P

361161-79-7P 361161-80-0P 361161-81-1P

361161-83-3P 361161-84-4P 361161-85-5P

361161-98-0P 361161-99-1P 361162-00-7P

361162-01-8P 361162-02-9P 361162-03-0P

361162-04-1P 361162-05-2P 361162-06-3P

361162-07-4P 361162-08-5P 361162-10-9P


361162-12-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2-heterocyclyl-4-phenyldihydropyrimidines as antiviral agents for treatment of hepatitis B infection)


RN 361161-74-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)




RN 361161-75-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, 2-cyanoethyl ester (9CI) (CA INDEX NAME)




RN 361161-77-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(3-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(2-methoxyethyl)-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)




RN 361161-79-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl- (9CI) (CA INDEX NAME)




RN 361161-80-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl- (9CI) (CA INDEX NAME)




RN 361161-81-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(3-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 361161-83-3 CAPLUS

CN 1H-Imidazole, 1-[[4-(2-chloro-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 361161-84-4 CAPLUS

CN 1H-Imidazole, 1-[[4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 361161-85-5 CAPLUS

CN 1H-Imidazole, 1-[[4-(3-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(2-methoxyethyl)-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 361161-98-0 CAPLUS

5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-, 1,4-dihydro-6-methyl-, hydrazide (9CI) (CA INDEX NAME)




RN 361161-99-1 CAPLUS

5-Pyrimidinecarboxamide, 4-(2-chloro-4-fluorophenyl)-N-(2-cyanoethyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl- (9CI) (CA INDEX NAME)




RN 361162-00-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2-chloro-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-N-(2-hydroxyethoxy)-6-methyl- (9CI) (CA INDEX NAME)




RN 361162-01-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, hydrazide (9CI) (CA INDEX NAME)




RN 361162-02-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, 2-formylhydrazide (9CI) (CA INDEX NAME)



RN 361162-03-0 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, 2-(aminocarbonyl)hydrazide (9CI) (CA INDEX NAME)



RN 361162-04-1 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, 2-(aminothioxomethyl)hydrazide (9CI) (CA INDEX NAME)






RN 361162-05-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, 2-acetylhydrazide (9CI) (CA INDEX NAME)




RN 361162-06-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-N-(2-hydroxyethoxy)-6-methyl- (9CI) (CA INDEX NAME)




RN 361162-07-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-N-(2-hydroxyethyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 361162-08-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(3-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(2-methoxyethyl)-, 2-formylhydrazide (9CI) (CA INDEX NAME)




RN 361162-10-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(3-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(2-methoxyethyl)-, 2-acetylhydrazide (9CI) (CA INDEX NAME)



RN 361162-12-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-N-(2-hydroxyethoxy)-6-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RE.CNT 2      THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:693316 CAPLUS

DN 135:242246

TI Preparation of 2-heterocyclyl-4-phenyldihydropyrimidine-5-carboxylates as antiviral agents for treatment of hepatitis B infection

IN Goldmann, Siegfried; Stoltefuss, Juergen; Niewoehner, Ulrich; Schlemmer, Karl-Heinz; Kraemer, Thomas; Paessens, Arnold; Graef, Erwin; Weber, Olaf; Deres, Karl

PA Bayer Aktiengesellschaft, Germany

SO PCT Int. Appl., 67 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001068642	A1	20010920	WO 2001-EP2444	20010305
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 10012824	A1	20010920	DE 2000-10012824	20000316
PRAI	DE 2000-10012824	A	20000316		

OS MARPAT 135:242246

AB Title compds. I and II [R1 = (substituted) Ph, furyl, thienyl; R2 = H, (substituted) alkyl, heteroalkyl; R3 = CH2(R8)mXR9; R8 = (substituted) alkyl, cycloalkyl; R9 = H, (substituted) aryl, heteroaryl, (O-interrupted) alkyl, cycloalkyl; X = O, S; m = 0, 1; R4 = H, alkyl, alkenyl, PhCO, Ac; R5 = (substituted) pyridyl, thiazolyl, thienyl, furyl], were prepared Thus, Me 6-bromomethyl-4-(2,4-dichlorophenyl)-2-(3,5-difluoropyridin-2-yl)-1,4-dihydropyrimidine-5-carboxylate was stirred with 4-mercaptopyridine Na salt in MeOH for 24 h to give 53.7% Me 4-(2,4-dichlorophenyl)-2-(3,5-difluoropyridin-2-yl)-1,4-dihydro-6-(4-pyridylthiomethyl)pyrimidine-5-carboxylate. Tested title compds. reduced intra- and/or extracellular viral DNA in hepatitis B virus-producing Hep G2.2.15-cells with IC50 = 0.05-0.8 µM.


IT 360783-70-6P 360783-72-8P 360783-74-0P  
 360783-75-1P 360783-77-3P 360783-80-8P  
 360783-82-0P 360783-83-1P 360783-84-2P  
 360783-85-3P 360783-86-4P 360783-87-5P  
 360783-88-6P 360783-89-7P 360783-93-3P  
 360783-94-4P 360783-95-5P 360783-96-6P  
 360783-97-7P 360783-98-8P 360783-99-9P  
 360784-00-5P 360784-01-6P 360784-02-7P  
 360784-04-9P 360784-05-0P 360784-06-1P  
 360784-07-2P 360784-08-3P 360784-09-4P  
 360784-10-7P 360784-11-8P 360784-12-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of heterocyclylphenyldihydropyrimidinecarboxylates as antiviral agents for treatment of hepatitis B infection)

RN 360783-70-6 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[(2-methoxyethoxy)methyl]-, methyl ester (9CI)  
(CA INDEX NAME)



RN 360783-72-8 CAPLUS  
CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(4-pyridinylthio)methyl]-, methyl ester (9CI)  
(CA INDEX NAME)




RN 360783-74-0 CAPLUS  
CN 5-Pyrimidinecarboxylic acid, 4-(4-chloro-2-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[(2-methoxyethoxy)methyl]-, ethyl ester (9CI)  
(CA INDEX NAME)




RN 360783-75-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-chloro-2-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(2-methoxyethoxy)methyl]-, ethyl ester (9CI)  
(CA INDEX NAME)




RN 360783-77-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(2-methoxyethoxy)methyl]-, ethyl ester (9CI)  
(CA INDEX NAME)




RN 360783-80-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-chlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(2-methoxyethoxy)methyl]-, ethyl ester (9CI)  
(CA INDEX NAME)



RN 360783-82-0 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[(2-methoxyethoxy)methyl]-, ethyl ester (9CI)  
(CA INDEX NAME)



RN 360783-83-1 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-chlorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[(2-methoxyethoxy)methyl]-, ethyl ester (9CI)  
(CA INDEX NAME)






RN 360783-84-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(2-methoxyethoxy)methyl]-, methyl ester (9CI)  
(CA INDEX NAME)




RN 360783-85-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[(2-methoxyethoxy)methyl]-, methyl ester (9CI)  
(CA INDEX NAME)




RN 360783-86-4 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-chlorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[(2-methoxyethoxy)methyl]-, methyl ester (9CI)  
(CA INDEX NAME)



RN 360783-87-5 CAPLUS  
CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-chlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(2-methoxyethoxy)methyl]-, methyl ester (9CI)  
(CA INDEX NAME)




RN 360783-88-6 CAPLUS  
CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(2-methoxyethoxy)methyl]-, methyl ester (9CI)  
(CA INDEX NAME)




RN 360783-89-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-1,4-dihydro-6-[(2-methoxyethoxy)methyl]-2-(3-methyl-2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 360783-93-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[[2-(1-methylethoxy)ethoxy)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 360783-94-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-chloro-2-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[[2-(1-methylethoxy)ethoxy)methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 360783-95-5 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[2-(phenylmethoxy)ethoxy)methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 360783-96-6 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[2-(phenylmethoxy)ethoxy)methyl]-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 360783-97-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[2-(1-methylethoxy)ethoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 360783-98-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[[2-(1-methylethoxy)ethoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 360783-99-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(3,4-difluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(2-methoxyethoxy)methyl]-, ethyl ester (9CI)  
(CA INDEX NAME)




RN 360784-00-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[(2-methoxyethoxy)methyl]-, ethyl ester (9CI)  
(CA INDEX NAME)




RN 360784-01-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(2-methoxyethoxy)methyl]-, ethyl ester (9CI)  
(CA INDEX NAME)




RN 360784-02-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(2-hydroxyethoxy)methyl]-, methyl ester (9CI)  
(CA INDEX NAME)




RN 360784-04-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[(2-methoxyethoxy)methyl]-, ethyl ester (9CI)  
(CA INDEX NAME)




RN 360784-05-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[[2-(1-methylethoxy)ethoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 360784-06-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-chlorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[[2-(1-methylethoxy)ethoxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 360784-07-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-bromo-2-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[2-methoxyethoxy]methyl]-, ethyl ester (9CI)




(CA INDEX NAME)



RN 360784-08-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[(2-hydroxyethoxy)methyl]-, methyl ester (9CI)  
(CA INDEX NAME)



RN 360784-09-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(2-methoxyethoxy)methyl]-, methyl ester, (4R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 360784-10-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(2-pyrimidinylthio)methyl]-, methyl ester, (4R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 360784-11-8 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-[[ (4,5-dihydro-2-thiazolyl)thio]methyl]-1,4-dihydro-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 360784-12-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(2-methoxyethoxy)methyl]-, methyl ester (9CI)  
(CA INDEX NAME)




IT **360783-73-9**

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of heterocyclylphenyldihydropyrimidinecarboxylates as antiviral agents for treatment of hepatitis B infection)

RN 360783-73-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 6-(bromomethyl)-4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-, methyl ester (9CI) (CA INDEX NAME)




IT **360783-68-2P 360783-69-3P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heterocyclphenyldihydropyrimidinecarboxylates as antiviral agents for treatment of hepatitis B infection)


RN 360783-68-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 360783-69-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-6-(bromomethyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 3      THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:693315 CAPLUS

DN 135:242245

TI Preparation of 6-aminoalkyl-2-heterocyclyl-4-phenyldihydropyrimidine-5-carboxylates as antiviral agents for treatment of hepatitis B infection.

IN Goldmann, Siegfried; Stoltefuss, Juergen; Niewoehner, Ulrich; Schlemmer, Karl-Heinz; Keldenich, Joerg; Paessens, Arnold; Graef, Erwin; Weber, Olaf; Deres, Karl

PA Bayer Aktiengesellschaft, Germany

SO PCT Int. Appl., 85 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001068641	A1	20010920	WO 2001-EP2443	20010305
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 10013126	A1	20010920	DE 2000-10013126	20000317
PRAI	DE 2000-10013126	A	20000317		

OS MARPAT 135:242245

AB Title compds. I and II [R1 = (substituted) pyridyl, pyrimidyl, pyrazinyl, thiazolyl; R2 = (substituted) aryl, heteroaryl; R3 = (substituted) (O-, S-interrupted) alkyl; R4 = (substituted) alkyl, aryl, heteroaryl, etc.; R5 = H, (substituted) (interrupted) alkyl, heteroaryl, etc.; R4R5 = (substituted) (interrupted) cycloalkyl, etc.; X = (substituted) (O-interrupted) alkylene], were prepared Thus, Me (R)-6-bromomethyl-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydropyrimidine-5-carboxylate (preparation given) was stirred with Na<sub>2</sub>CO<sub>3</sub> and 1-cyclopropylpiperazine dihydrochloride in MeOH for 2 h at room temperature to give 87.6% Me (R)-4-(2-chloro-4-fluorophenyl)-6-[(4-cyclopropyl-1-piperazinyl)methyl]-2-(2,3-difluoro-2-pyridinyl)-1,4-dihydropyrimidine-5-carboxylate. Several title compds. inhibited intra- or extracellular DNA of hepatitis B virus-producing Hep G2.2.15-cells with inhibited with IC<sub>50</sub> = 0.015-0.08 µM.

IT 360793-12-0P 360793-13-1P 360793-14-2P  
 360793-15-3P 360793-16-4P 360793-17-5P  
 360793-18-6P 360793-19-7P 360793-20-0P  
 360793-21-1P 360793-22-2P 360793-23-3P  
 360793-24-4P 360793-25-5P 360793-26-6P  
 360793-27-7P 360793-28-8P 360793-29-9P  
 360793-30-2P 360793-31-3P 360793-32-4P  
 360793-33-5P 360793-34-6P 360793-35-7P  
 360793-36-8P 360793-37-9P 360793-38-0P  
 360793-39-1P 360793-40-4P 360793-41-5P  
 360793-42-6P 360793-43-7P 360793-44-8P  
 360793-45-9P 360793-46-0P 360793-47-1P  
 360793-48-2P 360793-49-3P 360793-50-6P  
 360793-54-0P 360793-55-1P 360793-56-2P  
 360793-57-3P 360793-58-4P 360793-59-5P

360793-60-8P 360793-61-9P 360793-62-0P  
 360793-63-1P 360793-64-2P 360793-65-3P  
 360793-66-4P 360793-67-5P 360793-68-6P  
 360793-69-7P 360793-70-0P 360793-71-1P  
 360793-72-2P 360793-73-3P 360793-74-4P  
 360793-75-5P 360793-76-6P 360793-77-7P  
 360793-79-9P 360793-80-2P 360793-81-3P  
 360793-82-4P 360793-83-5P 360793-84-6P  
 360793-85-7P 360793-86-8P 360793-87-9P  
 360793-88-0P 360793-89-1P 360793-90-4P  
 360793-91-5P 360793-92-6P 360793-93-7P  
 360793-94-8P 360793-95-9P 360793-96-0P  
 360793-97-1P 360793-98-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminoalkylheterocyclphenyldihydropyrimidinecarboxylates as antiviral agents for treatment of hepatitis B infection.)

RN 360793-12-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-6-[(4-cyclopropyl-1-piperazinyl)methyl]-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 360793-13-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(3-hydroxy-1-pyrrolidinyl)methyl]-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 360793-14-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(4-hydroxy-1-piperidinyl)methyl]-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 360793-15-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(3-hydroxy-1-piperidinyl)methyl]-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 360793-16-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[4-(2-pyridinyl)-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 360793-17-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 360793-18-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 360793-19-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(4-phenyl-1-piperazinyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 360793-20-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(4-hydroxy-1-piperidinyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 360793-21-1 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 6-[(4-acetyl-1-piperazinyl)methyl]-4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-, methyl ester (9CI) (CA INDEX NAME)



RN 360793-22-2 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[3-(hydroxymethyl)-1-piperidinyl]methyl]-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 360793-23-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[[4-(2-pyridinyl)-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 360793-24-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 6-[(4-acetyl-1-piperazinyl)methyl]-4-(2,4-dichlorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-, methyl ester (9CI) (CA INDEX NAME)



RN 360793-25-5 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[[4-(2-pyridinyl)-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 360793-26-6 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

methyl ester (9CI) (CA INDEX NAME)




RN 360793-27-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[(4-phenyl-1-piperazinyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 360793-28-8 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 6-[(4-acetyl-1-piperazinyl)methyl]-4-(2-bromo-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-, methyl ester (9CI) (CA INDEX NAME)



RN 360793-29-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-[[ (2S,6R)-2,6-dimethyl-4-morpholinyl]methyl]-1,4-dihydro-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 360793-30-2 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-[[[2-(dimethylamino)ethyl]ethylamino]methyl]-1,4-dihydro-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 360793-31-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-[[[4-(2-pyridinyl)-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 360793-32-4 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(4-phenyl-1-piperazinyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 360793-33-5 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(4-hydroxy-1-piperidinyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)






RN 360793-34-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 6-[(4-acetyl-1-piperazinyl)methyl]-4-(2-bromo-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-, methyl ester (9CI) (CA INDEX NAME)




RN 360793-35-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(3-hydroxy-1-piperidinyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 360793-36-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[4-(phenylmethyl)-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 360793-37-9 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-(1,4-dioxo-8-azaspiro[4.5]dec-8-ylmethyl)-1,4-dihydro-, methyl ester (9CI) (CA INDEX NAME)



RN 360793-38-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[2-hydroxyethyl)(2-methoxyethyl)amino]methyl]-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 360793-39-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-[[ethyl(2-furanylmethyl)amino]methyl]-1,4-dihydro-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 360793-40-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-[(1,1-dioxido-4-thiomorpholinyl)methyl]-1,4-dihydro-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 360793-41-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-[(4-formyl-1-piperazinyl)methyl]-1,4-dihydro-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 360793-42-6 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 6-[[[(2-amino-2-oxoethyl)methylamino]methyl]-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 360793-43-7 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[[[4-(2-pyridinyl)-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 360793-44-8 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 6-[[[(3-amino-3-oxopropyl)methylamino]methyl]-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 360793-45-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 360793-46-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 360793-47-1 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[[2-(hydroxyethyl)(2-methoxyethyl)amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 360793-48-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-[[4-(5-fluoro-2-pyrimidinyl)-1-piperazinyl]methyl]-1,4-dihydro-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 360793-49-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-[[4-[(1,1-dimethylethoxy)carbonyl]-1-piperazinyl]methyl]-1,4-dihydro-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 360793-50-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]methyl]-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 360793-54-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(4-oxo-1-piperidinyl)methyl]-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 360793-55-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[4-(2-pyrimidinyl)-1-piperazinyl]methyl]-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 360793-56-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(3-oxo-1-piperazinyl)methyl]-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 360793-57-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-[[2-(furanylmethyl)methylamino]methyl]-1,4-dihydro-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 360793-58-4 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(2-oxo-1-pyrrolidinyl)methyl]-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 360793-59-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(4-morpholinylamino)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 360793-60-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[methyl(4-pyridinylmethyl)amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 360793-61-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[2-(hydroxymethyl)-1-piperidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 360793-62-0 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-(1,4-dioxo-7-azaspiro[4.4]non-7-ylmethyl)-1,4-dihydro-, methyl ester (9CI) (CA INDEX NAME)



RN 360793-63-1 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(3-oxo-4-morpholinyl)methyl]-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 360793-64-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(methyl-4-morpholinylamino)methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 360793-65-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(methyl-4-morpholinylamino)methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 360793-66-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 6-[(4-acetylhexahydro-1H-1,4-diazepin-1-yl)methyl]-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 360793-67-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[4-(2-methylbenzoyl)-1-piperazinyl]methyl]-, methyl ester, monohydrochloride, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 360793-68-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-[[[(3R,4S)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-methoxy-1-pyrrolidinyl]methyl]-1,4-dihydro-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 360793-69-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(1-oxido-4-thiomorpholinyl)methyl]-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.





RN 360793-70-0 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[4-(phenoxy-carbonyl)-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 360793-71-1 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-[[3-[(dimethylamino)methyl]-3-hydroxy-1-pyrrolidinyl]methyl]-1,4-dihydro-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 360793-72-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(2-oxa-5-azabicyclo[2.2.1]hept-5-ylmethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 360793-73-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 6-[(4-benzoyl-1-piperazinyl)methyl]-4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-, methyl ester (9CI) (CA INDEX NAME)



RN 360793-74-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[3-(hydroxymethyl)-1-pyrrolidinyl]methyl]-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 360793-75-5 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[[2-(2-hydroxyethoxy)ethyl]methylamino]methyl]-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 360793-76-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[(methyl-4-morpholinylamino)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 360793-77-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[[4-[(phenylmethoxy)carbonyl]-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 360793-79-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-(2-oxa-5-azabicyclo[2.2.1]hept-5-ylmethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 360793-80-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(2-oxa-5-azabicyclo[2.2.1]hept-5-ylmethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 360793-81-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[4-(phenoxy carbonyl)-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 360793-82-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(9-methyl-6-oxa-2,9-diazaspiro[4.5]dec-2-yl)methyl]-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 360793-83-5 CAPLUS

CN Pyrrolo[3,4-b]-1,4-oxazine-6(2H)-carboxylic acid, 4-[[ (6R)-6-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,6-dihydro-5-(methoxycarbonyl)-4-pyrimidinyl)methyl]hexahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 360793-84-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[4-(trifluoroacetyl)-1-piperazinyl]methyl]-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 360793-85-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-[[[(3aS,4R,7aR)-1,3,3a,4,7,7a-hexahydro-4-(hydroxymethyl)-3a,7a-dimethyl-2H-isoindol-2-yl]methyl]-1,4-dihydro-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 360793-86-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]methyl]-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 360793-87-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-6-[[4-[(2,4-difluorophenoxy)acetyl]-1-piperazinyl]methyl]-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 360793-88-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(3-oxa-8-azabicyclo[3.2.1]oct-8-ylmethyl)-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 360793-89-1 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(8-oxa-3-azabicyclo[3.2.1]oct-3-ylmethyl)-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 360793-90-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[[methyl[2-(4-morpholinyl)ethyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 360793-91-5 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[[4-(phenoxycarbonyl)-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 360793-92-6 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-[[ethyl(2-methoxyethyl)amino]methyl]-1,4-dihydro-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 360793-93-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[[4-(methoxycarbonyl)-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 360793-94-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[4-(methoxycarbonyl)-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 360793-95-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[4-(methoxycarbonyl)-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 360793-96-0 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[[4-(methoxycarbonyl)-1-piperazinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 360793-97-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(tetrahydro-1,6a-dimethyl-1H-pyrrolo[3,4-c]isoxazol-5(3H)-yl)methyl]-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 360793-98-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-[[3-fluoro-3-(hydroxymethyl)-1-pyrrolidinyl]methyl]-1,4-dihydro-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 298708-79-9P 360793-11-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aminoalkylheterocyclylphenyldihydropyrimidinecarboxylates as antiviral agents for treatment of hepatitis B infection.)

RN 298708-79-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-


pyridinyl)-1,4-dihydro-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 360793-11-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 6-(bromomethyl)-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:693314 CAPLUS

DN 135:242244

TI Preparation of 6-aminoalkyl-2-heterocyclyl-4-phenyldihydropyrimidine-5-carboxylates as antiviral agents for treatment of hepatitis B infection

IN Goldmann, Siegfried; Stoltefusz, Juergen; Niewoehner, Ulrich; Schlemmer, Karl-Heinz; Keldenich, Joerg; Paeszens, Arnold; Graef, Erwin; Weber, Olaf; Deres, Karl

PA Bayer Aktiengesellschaft, Germany

SO PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001068640	A1	20010920	WO 2001-EP2442	20010305
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 10012823	A1	20010920	DE 2000-10012823	20000316
	EP 1265889	A1	20021218	EP 2001-921313	20010305
	EP 1265889	B1	20040616		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	AT 269321	E	20040715	AT 2001-921313	20010305
	PT 1265889	T	20040930	PT 2001-921313	20010305
	ES 2222363	T3	20050201	ES 2001-1921313	20010305
	US 2003232842	A1	20031218	US 2003-221919	20030310
PRAI	DE 2000-10012823	A	20000316		
	WO 2001-EP2442	W	20010305		

OS MARPAT 135:242244

AB Title compds. I and II [R1, R2 = H, F, Cl, Br; R3 = alkyl; X = CH2, CH2CH2; Z = NR4R5, pyridyl; R4 = PhCH2, (substituted) alkyl; R5 = (OH-substituted) alkyl; NR4R5 = imidazolyl, triazolyl, tetrazolyl, heterocyclyl; R6 = (F-substituted) pyridyl, thiazolyl], were prepared Thus, Me (R)-6-bromomethyl-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridyl)-1,4-dihydropyrimidine-5-carboxylate (preparation given) in MeOH was stirred with piperidine for 30 min. at room temperature to give 69% Me (R)-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridyl)-6-piperidinomethyl-1,4-dihydropyrimidine-5-carboxylate. Tested title compds. reduced hepatitis B intra- and/or extracellular DNA by virus producing Hep G2.2.15 cells with IC50 = 0.002-0.4 µM.

IT 361204-32-2P 361204-33-3P 361204-34-4P  
 361204-35-5P 361204-36-6P 361204-37-7P  
 361204-38-8P 361204-39-9P 361204-40-2P  
 361204-41-3P 361204-42-4P 361204-43-5P  
 361204-44-6P 361204-45-7P 361204-46-8P  
 361204-47-9P 361204-48-0P 361204-49-1P  
 361204-50-4P 361204-51-5P 361204-52-6P  
 361204-53-7P 361204-54-8P 361204-55-9P  
 361204-56-0P 361204-57-1P 361204-58-2P


361204-59-3P 361204-60-6P 361204-61-7P  
 361204-62-8P 361204-63-9P 361204-64-0P  
 361204-65-1P 361204-66-2P 361204-67-3P  
 361204-68-4P 361204-69-5P 361204-70-8P  
 361204-71-9P 361204-72-0P 361204-73-1P  
 361204-74-2P 361204-75-3P 361204-80-0P  
 361204-81-1P 361204-82-2P 361204-83-3P  
 361204-84-4P 361204-85-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminoalkylheterocyclphenyldihydropyrimidinecarboxylates as antiviral agents for treatment of hepatitis B infection)


RN 361204-32-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(4-morpholinymethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 361204-33-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[2-(3-thiazolidinyl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 361204-34-4 CAPLUS




CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[2-(4-pyridinyl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 361204-35-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(1-piperidinylmethyl)-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 361204-36-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(4-morpholinylmethyl)-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 361204-37-7 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-6-[(diethylamino)methyl]-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 361204-38-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-(4-morpholinylmethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 361204-39-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-(1-piperidinylmethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 361204-40-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(4-morpholinylmethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 361204-41-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(1-pyrrolidinylmethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 361204-42-4 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(4-thiomorpholinylmethyl)-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 361204-43-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(4-morpholinylmethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 361204-44-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(1-pyrrolidinylmethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 361204-45-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(3-thiazolidinylmethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 361204-46-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(4-thiomorpholinylmethyl)-, methyl ester (9CI)  
(CA INDEX NAME)



RN 361204-47-9 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-[(ethylmethylamino)methyl]-1,4-dihydro-, methyl ester (9CI)  
(CA INDEX NAME)



RN 361204-48-0 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-[[ethyl(2-hydroxyethyl)amino]methyl]-1,4-dihydro-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 361204-49-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-(4-thiomorpholinylmethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 361204-50-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-(3-thiazolidinylmethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 361204-51-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-(4-thiomorpholinylmethyl)-, methyl ester (9CI)  
(CA INDEX NAME)




RN 361204-52-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-(3-thiazolidinylmethyl)-, methyl ester (9CI) (CA




INDEX NAME)



RN 361204-53-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 6-[[bis(2-hydroxyethyl)amino]methyl]-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 361204-54-8 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[[(2-hydroxyethyl)methylamino]methyl]-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 361204-55-9 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-(4-morpholinylmethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 361204-56-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-[(hexahydro-1H-azepin-1-yl)methyl]-1,4-dihydro-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 361204-57-1 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-[(dimethylamino)methyl]-1,4-dihydro-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 361204-58-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 6-[[bis(2-hydroxyethyl)amino]methyl]-4-(2,4-dichlorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-, methyl ester (9CI) (CA INDEX NAME)




RN 361204-59-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(3-thiazolidinylmethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 361204-60-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(4-thiomorpholinylmethyl)-, methyl ester (9CI)  
(CA INDEX NAME)




RN 361204-61-7 CAPLUS  
 CN 5-Pyrimidinecarboxylic acid, 6-[[bis(2-hydroxyethyl)amino]methyl]-4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-, methyl ester (9CI) (CA INDEX NAME)




RN 361204-62-8 CAPLUS  
 CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(4-morpholinylmethyl)-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 361204-63-9 CAPLUS  
 CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[ (2-hydroxyethyl)methylamino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 361204-64-0 CAPLUS


5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[ (2-hydroxyethyl) (2-methylpropyl) amino]methyl]-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 361204-65-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-(4-morpholinylmethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 361204-66-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[[ (2-hydroxyethyl)methylamino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 361204-67-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-(4-thiomorpholinylmethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 361204-68-4 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-(3-thiazolidinylmethyl)-, methyl ester (9CI) (CA

## INDEX NAME)




RN 361204-69-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 6-[[bis(2-hydroxyethyl)amino]methyl]-4-(2-chloro-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-, methyl ester (9CI) (CA INDEX NAME)



RN 361204-70-8 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[[[(2-hydroxyethyl)(phenylmethyl)amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 361204-71-9 CAPLUS




CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[ (2-hydroxyethyl) (phenylmethyl) amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 361204-72-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[[ (2-hydroxyethyl) (phenylmethyl) amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 361204-73-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[ (2-hydroxyethyl) (phenylmethyl) amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 361204-74-2 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[[2-hydroxyethyl)(phenylmethyl)amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 361204-75-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(1H-imidazol-1-ylmethyl)-, methyl ester, (4R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 361204-80-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-[[[2-(1,1-dimethylethoxy)-2-oxoethyl]methylamino]methyl]-1,4-dihydro-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 361204-81-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[[2-(1,1-dimethylethoxy)-2-oxoethyl]methylamino]methyl]-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 361204-82-2 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[[2-(2-hydroxyethyl)(2-hydroxypropyl)amino]methyl]-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 361204-83-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(1H-imidazol-1-ylmethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 361204-84-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(1H-tetrazol-1-ylmethyl)-, methyl ester (9CI)  
(CA INDEX NAME)



RN 361204-85-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(2H-tetrazol-2-ylmethyl)-, methyl ester (9CI)  
(CA INDEX NAME)




IT **298708-79-9P 360793-11-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aminoalkylheterocyclphenyldihydropyrimidinecarboxylates as antiviral agents for treatment of hepatitis B infection)

RN 298708-79-9 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 360793-11-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 6-(bromomethyl)-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3      THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:693313 CAPLUS

DN 135:242243

TI Preparation of 2-heterocyclyl-4-phenyldihydropyrimidine-5-carboxylates as antiviral agents for treatment of hepatitis B infection

IN Goldmann, Siegfried; Stoltefuss, Juergen; Niewoehner, Ulrich; Schlemmer, Karl-Heinz; Kraemer, Thomas; Paessens, Arnold; Graef, Erwin; Weber, Olaf; Deres, Karl

PA Bayer Aktiengesellschaft, Germany

SO PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001068639	A1	20010920	WO 2001-EP2441	20010305
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 10013125	A1	20010920	DE 2000-10013125	20000317
PRAI	DE 2000-10013125	A	20000317		

OS MARPAT 135:242243

AB Title compds. I and II [R1 = dihalophenyl; R2 = Me, Et; R3 = CH<sub>2</sub>(R<sub>8</sub>)mXnR<sub>9</sub>; R<sub>8</sub> = CR<sub>10</sub>R<sub>11</sub>; R<sub>10</sub> = H, OH, Me; R<sub>11</sub> = H, Me; X = O; R<sub>9</sub> = (azido-substituted) alkyl; R<sub>4</sub> = H; R<sub>5</sub> = (substituted) pyridyl, thiazolyl; m, n = 0, 1; n = 1 if m = 0; n = 0 if m = 1; R<sub>3</sub> contains ≥1 O], were prepared. Thus, Me isopropoxyacetylacetate (preparation given), 2-chloro-4-fluorobenzaldehyde, and 3,5-difluoro-2-pyridinecarboxamide diacetate (analog preparation given) were refluxed 16 h in MeOH to give 5.5% Me 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-(isopropoxymethyl)-1,4-dihydropyrimidine-5-carboxylate. Tested title compds. inhibited intra- and/or extracellular DNA of hepatitis B virus-producing Hep G2.2.15-cells with IC<sub>50</sub> = 0.06-0.3 μM.

IT 360788-32-5P 360788-33-6P 360788-34-7P  
360788-35-8P 360788-37-0P 360788-38-1P  
360788-39-2P 360788-40-5P 360788-41-6P  
360788-42-7P 360788-43-8P 360788-46-1P  
360788-47-2P 360788-48-3P 360788-49-4P  
360788-50-7P 360788-51-8P 360788-52-9P  
360788-53-0P 360788-54-1P 360788-55-2P  
360788-56-3P 360788-57-4P 360788-58-5P  
360788-59-6P 360788-60-9P 360788-61-0P  
360788-63-2P 360788-64-3P 360788-65-4P  
360788-66-5P 360788-67-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of heterocyclylphenyldihydropyrimidinecarboxylates as antiviral agents for treatment of hepatitis B infection)

RN 360788-32-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-




pyridinyl)-1,4-dihydro-6-[(1-methylethoxy)methyl]-, methyl ester (9CI)  
(CA INDEX NAME)




RN 360788-33-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-(ethoxymethyl)-1,4-dihydro-, ethyl ester (9CI) (CA INDEX NAME)




RN 360788-34-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-(ethoxymethyl)-1,4-dihydro-, ethyl ester (9CI) (CA INDEX NAME)




RN 360788-35-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-6-(ethoxymethyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-, ethyl ester (9CI) (CA INDEX NAME)




RN 360788-37-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(2-methoxyethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 360788-38-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-chloro-2-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-(ethoxymethyl)-1,4-dihydro-, ethyl ester (9CI) (CA INDEX NAME)




RN 360788-39-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-(ethoxymethyl)-1,4-dihydro-, methyl ester (9CI) (CA INDEX NAME)




RN 360788-40-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-(methoxymethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 360788-41-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(methoxymethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 360788-42-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-difluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-(ethoxymethyl)-1,4-dihydro-, ethyl ester (9CI) (CA INDEX NAME)




RN 360788-43-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-(ethoxymethyl)-1,4-dihydro-, ethyl ester (9CI) (CA INDEX NAME)




RN 360788-46-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(3,4-difluorophenyl)-6-(ethoxymethyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-, ethyl ester (9CI) (CA INDEX NAME)




RN 360788-47-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-6-(ethoxymethyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-, ethyl ester (9CI) (CA INDEX NAME)




RN 360788-48-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-6-(ethoxymethyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-, ethyl ester (9CI) (CA INDEX NAME)




RN 360788-49-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-6-(ethoxymethyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-, methyl ester (9CI) (CA INDEX NAME)




RN 360788-50-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-bromo-2-fluorophenyl)-6-(ethoxymethyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-, ethyl ester (9CI) (CA INDEX NAME)




RN 360788-51-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-bromo-2-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-(ethoxymethyl)-1,4-dihydro-, ethyl ester (9CI) (CA INDEX NAME)



RN 360788-52-9 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-chlorophenyl)-2-(3-chloro-2-pyridinyl)-6-(ethoxymethyl)-1,4-dihydro-, ethyl ester (9CI) (CA INDEX NAME)



RN 360788-53-0 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3-fluoro-2-

pyridinyl)-1,4-dihydro-6-(2-hydroxybutyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 360788-54-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(2-hydroxybutyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 360788-55-2 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-6-(ethoxymethyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-, methyl ester (9CI) (CA INDEX NAME)





RN 360788-56-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-(ethoxymethyl)-1,4-dihydro-, methyl ester (9CI) (CA INDEX NAME)



RN 360788-57-4 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(methoxymethyl)-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 360788-58-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[(1-methylethoxy)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 360788-59-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-[(1-methylethoxy)methyl]-, methyl ester (9CI)  
(CA INDEX NAME)




RN 360788-60-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-[(1-methylethoxy)methyl]-, methyl ester (9CI)  
(CA INDEX NAME)




RN 360788-61-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-(propoxymethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 360788-63-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(2-hydroxy-3-methylbutyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 360788-64-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(2-hydroxy-2-methylpropyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 360788-65-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-(ethoxymethyl)-1,4-dihydro-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 360788-66-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-(ethoxymethyl)-1,4-dihydro-, ethyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 360788-67-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-(2-methoxyethyl)-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **360783-68-2P 360783-69-3P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heterocyclphenyldihydropyrimidinecarboxylates as antiviral agents for treatment of hepatitis B infection)


RN 360783-68-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 360783-69-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-4-fluorophenyl)-6-(bromomethyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2001:661495 CAPLUS  
 DN 135:221261  
 TI Synthesis of isoxazoles and usage as anti HPV agent  
 IN Brands, Michael; Nikolic, Susanne; Eckenberg, Peter; Bauser, Marcus;  
 Kaulen, Johannes; Paessens, Arnold; Graef, Erwin; Weber, Olaf; Lottmann,  
 Stefan; Schlemmer, Karl-heinz  
 PA Bayer A.-G., Germany  
 SO PCT Int. Appl., 76 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA German  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001064755	A2	20010907	WO 2001-EP1825	20010219
	WO 2001064755	A3	20020620		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				
	HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				
	LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				
	SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,				
	YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 10009408	A1	20010830	DE 2000-10009408	20000228
	DE 10032874	A1	20020117	DE 2000-10032874	20000706
	CA 2401405	AA	20010907	CA 2001-2401405	20010219
	BR 2001008723	A	20021203	BR 2001-8723	20010219
	EP 1286974	A2	20030305	EP 2001-909773	20010219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003526639	T2	20030909	JP 2001-564248	20010219
	US 2003187028	A1	20031002	US 2003-220110	20030121
PRAI	DE 2000-10009408	A	20000228		
	DE 2000-10032874	A	20000706		
	WO 2001-EP1825	W	20010219		

OS MARPAT 135:221261

AB The invention concerns the synthesis of isoxazoles ((I), R groups are defined) and their usage as highly effective anti-viral agents. Combinations of isoxazoles, dihydropyrimidines and/or HBV polymerase inhibitors e.g. lamivudine, phenylpropeneamide derivs., and optionally, interferon inhibit the proliferation of HBV viruses better than conventional agents.


IT 298708-81-3 298708-83-5

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (synthesis of isoxazoles and usage as anti HPV agent)

RN 298708-81-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 298708-83-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).





L4 ANSWER 18 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2001:472499 CAPLUS  
 DN 135:56051  
 TI Dihydropyrimidine-HBV antiviral-immunomodulator combinations for treating hepatitis B infection  
 IN Paessens, Arnold; Deres, Karl; Weber, Olaf; Graef, Erwin; Goldmann, Siegfried; Kramer, Thomas; Niewohner, Ulrich; Schlemmer, Karl-Heinz; Stoltefuss, Jurgen  
 PA Bayer Aktiengesellschaft, Germany  
 SO PCT Int. Appl., 107 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001045712	A1	20010628	WO 2000-EP12570	20001212
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 19962010	A1	20010628	DE 1999-19962010	19991222
	DE 10012259	A1	20010920	DE 2000-10012259	20000314
PRAI	DE 1999-19962010	A	19991222		
	DE 2000-10012259	A	20000314		

OS MARPAT 135:56051

AB The invention provides combinations of dihydropyrimidines, an antiviral agent (e.g. lamivudine), and an immunomodulator (e.g. interferon) for inhibition of the multiplication of HBV viruses better than conventional agents.

IT **298708-81-3 298708-81-3D, isomers 298708-83-5 298708-83-5D, isomers**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(dihydropyrimidine-HBV antiviral-immunomodulator combination for treating hepatitis B infection)

RN 298708-81-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 298708-81-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 298708-83-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 298708-83-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2001:235559 CAPLUS  
 DN 134:266319  
 TI CD40 function inhibitors containing (hetero)aryl compounds and their preparation  
 IN Saito, Shoichi; Akane, Katsura; Fujimoto, Katsumi; Shiraishi, Akio; Kurakata, Shinichi; Maeda, Hiroaki; Tatsuta, Toru  
 PA Sankyo Co., Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 139 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001089452	A2	20010403	JP 1999-267909	19990922
PRAI	JP 1999-267909		19990922		
OS	MARPAT 134:266319				

AB Title inhibitors, useful for prevention and treatment of allergy, rheumatoid, autoimmune disease, and arteriosclerosis, contain aromatic compds. I [R1, R3, R4 = H, OH, halo, C1-15 alkyl(oxy), C1-15 alkylthio, (un)substituted (hetero)aryl, etc.; R2 = NO2, nitrile, CO2H, C2-6 alkoxy carbonyl; R1CCR2 may form (un)substituted (hetero)aryl; X, Y = N, CH] or their salts as active ingredients. Thus, MeOCPh:C(CO2Et)2 was refluxed with benzamidine HCl salt and NaH in EtOH for 5 h, evaporated, neutralized, extracted with AcOEt, the organic phase concentrated, and treated

with


POCl3 and morpholine to give 52% I (R1 = R4 = Ph, R2 = CO2Et, R3 = 4-morpholino, X = Y = N), which at 25  $\mu$ M inhibited 88% formation of IL-12.

IT 332071-03-1P 332071-05-3P 332071-07-5P  
 332071-08-6P 332071-09-7P 332071-11-1P  
 332071-12-2P 332071-13-3P 332071-33-7P  
 332071-34-8P 332071-35-9P 332071-36-0P  
 332071-37-1P 332071-38-2P 332071-39-3P  
 332071-40-6P 332071-41-7P 332071-42-8P  
 332071-45-1P 332071-47-3P 332071-53-1P  
 332071-55-3P 332071-56-4P 332071-57-5P  
 332071-58-6P 332071-61-1P 332071-62-2P  
 332071-63-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of (hetero)aryl compds. as CD40 function inhibitors)


RN 332071-03-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-morpholinyl)-6-phenyl-2-(3-pyridinyl)-, potassium salt (9CI) (CA INDEX NAME)




● K

RN 332071-05-3 CAPLUS  
 CN 5-Pyrimidinecarboxylic acid, 4-(4-morpholinyl)-6-phenyl-2-(4-pyridinyl)-, potassium salt (9CI) (CA INDEX NAME)




● K

RN 332071-07-5 CAPLUS  
 CN 5-Pyrimidinecarboxylic acid, 4-(4-morpholinyl)-6-(phenylmethyl)-2-(2-pyridinyl)-, potassium salt (9CI) (CA INDEX NAME)



● K


RN 332071-08-6 CAPLUS  
 CN 5-Pyrimidinecarboxylic acid, 4-(4-morpholinyl)-6-(phenylmethyl)-2-(3-pyridinyl)-, potassium salt (9CI) (CA INDEX NAME)



● K

RN 332071-09-7 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-morpholinyl)-6-(phenylmethyl)-2-(4-pyridinyl)-, potassium salt (9CI) (CA INDEX NAME)



● K

RN 332071-11-1 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-methyl-6-(4-morpholinyl)-2-(2-pyridinyl)-, potassium salt (9CI) (CA INDEX NAME)



● K

RN 332071-12-2 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-methyl-6-(4-morpholinyl)-2-(3-pyridinyl)-, potassium salt (9CI) (CA INDEX NAME)



● K

RN 332071-13-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-methyl-6-(4-morpholinyl)-2-(4-pyridinyl)-, potassium salt (9CI) (CA INDEX NAME)



● K

RN 332071-33-7 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(cyclohexylamino)-6-phenyl-2-(3-pyridinyl)-, monopotassium salt (9CI) (CA INDEX NAME)



● K

RN 332071-34-8 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-phenyl-6-(phenylamino)-2-(3-pyridinyl)-, monopotassium salt (9CI) (CA INDEX NAME)



● K

RN 332071-35-9 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-phenyl-6-(1-piperazinyl)-2-(3-pyridinyl)-, monopotassium salt (9CI) (CA INDEX NAME)



● K

RN 332071-36-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(diethylamino)-6-phenyl-2-(3-pyridinyl)-, potassium salt (9CI) (CA INDEX NAME)




● K

RN 332071-37-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-ethoxy-6-phenyl-2-(3-pyridinyl)-, potassium salt (9CI) (CA INDEX NAME)






● K

RN 332071-38-2 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(cyclohexyloxy)-6-phenyl-2-(3-pyridinyl)-, potassium salt (9CI) (CA INDEX NAME)



● K

RN 332071-39-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(heptyloxy)-6-phenyl-2-(3-pyridinyl)-, potassium salt (9CI) (CA INDEX NAME)



● K

RN 332071-40-6 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(pentyloxy)-6-phenyl-2-(3-pyridinyl)-, potassium salt (9CI) (CA INDEX NAME)



● K


RN 332071-41-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(methylthio)-6-phenyl-2-(3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 332071-42-8 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 1,4-dihydro-4-oxo-6-phenyl-2-(3-pyridinyl)-, disodium salt (9CI) (CA INDEX NAME)



●2 Na


RN 332071-45-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,4-dihydro-4-oxo-6-phenyl-2-(4-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 332071-47-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 1,4-dihydro-4-oxo-6-phenyl-2-(2-pyridinyl)-, disodium salt (9CI) (CA INDEX NAME)



●2 Na

RN 332071-53-1 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 1,4-dihydro-6-(1-naphthalenyl)-4-oxo-2-(3-pyridinyl)-, disodium salt (9CI) (CA INDEX NAME)



●2 Na


RN 332071-55-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-morpholinyl)-6-(phenylamino)-2-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 332071-56-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-morpholinyl)-6-(phenylamino)-2-(3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 332071-57-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-morpholinyl)-6-(phenylamino)-2-(4-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 332071-58-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(phenylamino)-2-(3-pyridinyl)-6-(4-thiomorpholinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 332071-61-1 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(phenylamino)-6-(1-piperazinyl)-2-(2-pyridinyl)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 332071-62-2 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(phenylamino)-6-(1-piperazinyl)-2-(3-pyridinyl)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 332071-63-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(phenylamino)-6-(1-piperazinyl)-2-(4-pyridinyl)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT **332071-95-1**

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of (hetero)aryl compds. as CD40 function inhibitors)

RN 332071-95-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-chloro-6-phenyl-2-(3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



IT **332071-77-9P 332071-79-1P 332071-80-4P**

**332071-81-5P 332071-84-8P 332071-85-9P**

**332071-86-0P 332071-87-1P 332071-91-7P**

**332071-92-8P 332071-93-9P 332071-94-0P**


**332072-00-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (hetero)aryl compds. as CD40 function inhibitors)


RN 332071-77-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-morpholinyl)-6-phenyl-2-(3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 332071-79-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-morpholinyl)-6-(phenylmethyl)-2-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 332071-80-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-morpholinyl)-6-(phenylmethyl)-2-(3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 332071-81-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-morpholinyl)-6-(phenylmethyl)-2-(4-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 332071-84-8 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-methyl-6-(4-morpholinyl)-2-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 332071-85-9 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-methyl-6-(4-morpholinyl)-2-(3-pyridinyl)-,

ethyl ester (9CI) (CA INDEX NAME)




RN 332071-86-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-methyl-6-(4-morpholinyl)-2-(4-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 332071-87-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,4-dihydro-4-oxo-6-phenyl-2-(3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 332071-91-7 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(cyclohexylamino)-6-phenyl-2-(3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)






RN 332071-92-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-phenyl-6-(phenylamino)-2-(3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 332071-93-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[4-[(1,1-dimethylethoxy)carbonyl]-1-piperazinyl]-6-phenyl-2-(3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 332071-94-0 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(diethylamino)-6-phenyl-2-(3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 332072-00-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,4-dihydro-6-(1-naphthalenyl)-4-oxo-2-(3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)

10/781,075



L4 ANSWER 20 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:911229 CAPLUS

DN 134:56687

TI Preparation of dihydropyrimidine derivatives as N-type calcium channel antagonists

IN Ohno, Seiji; Okajima, Akiko; Niwa, Seiji; Kito, Morikazu; Takahara, Akira; Ono, Yukitsugu; Kajigaya, Yuki; Takeda, Tomoko; Koganei, Hajime

PA Ajinomoto Co., Inc., Japan

SO PCT Int. Appl., 139 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000078730	A1	20001228	WO 2000-JP4107	20000622
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1193259	A1	20020403	EP 2000-940812	20000622
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2002143023	A1	20021003	US 2001-25589	20011226
US 6855716	B2	20050215		
PRAI JP 1999-177493	A	19990623		
JP 1999-277717	A	19990930		
WO 2000-JP4107	W	20000622		

OS MARPAT 134:56687

AB The title compds. I [R1 and R2 together form Q1, etc.; B2 = amino, etc.; A = 1-naphthyl, etc.; E = H, (un)substituted heteroaryl, etc.; C = H, alkyl, etc.; D = H, alkyl, etc.; L = O (with a proviso), etc.; Y = bond (with a proviso), etc.; X1 = CH2, etc.] are prepared I exhibit selective antagonist activity against the N-type calcium channel. In an in vitro test for N-type calcium channel antagonism, 4-(3-chlorophenyl)-6-[(2-cyclohexylethoxy)methyl]-5-(3,3-diphenylpropylcarbamoyl)-2-phenyl-1,4-dihydropyrimidine showed the pIC50 value of 5.9.


IT **313999-93-8P 313999-96-1P 313999-98-3P****314000-01-6P 314000-03-8P 314000-06-1P****314000-08-3P 314000-10-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of dihydropyrimidine derivs. as N-type calcium channel antagonists)


RN 313999-93-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,4-dichlorophenyl)-1,4-dihydro-6-methyl-N-(3-phenylpropyl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 313999-96-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,4-dichlorophenyl)-N-(3,3-diphenylpropyl)-1,4-dihydro-6-methyl-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 313999-98-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3-chlorophenyl)-N-(3,3-diphenylpropyl)-1,4-dihydro-6-methyl-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 314000-01-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3-chlorophenyl)-1,4-dihydro-6-methyl-N-(3-phenyl-2-propenyl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 314000-03-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-N-(3,3-diphenylpropyl)-1,4-dihydro-6-methyl-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 314000-06-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-1,4-dihydro-6-methyl-N-(3-phenylpropyl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 314000-08-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,4-dichlorophenyl)-1,4-dihydro-6-methyl-N-(3-phenyl-2-propenyl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 314000-10-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-1,4-dihydro-6-methyl-N-(3-phenyl-2-propenyl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2000:861658 CAPLUS  
 DN 134:29425  
 TI Novel 4-phenyl-pyrimidine derivatives as NK-1 receptor antagonists  
 IN Boes, Michael; Galley, Guido; Godel, Thierry; Hoffmann, Torsten; Hunkeler, Walter; Schnider, Patrick; Stadler, Heinz  
 PA F. Hoffmann-La Roche A.-G., Switz.  
 SO PCT Int. Appl., 64 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000073279	A1	20001207	WO 2000-EP4701	20000524
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6274588	B1	20010814	US 2000-575382	20000522
	TW 550258	B	20030901	TW 2000-89109829	20000522
	CA 2375671	AA	20001207	CA 2000-2375671	20000524
	BR 2000011127	A	20020219	BR 2000-11127	20000524
	EP 1187815	A1	20020320	EP 2000-927234	20000524
	EP 1187815	B1	20060208		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
	TR 200103457	T2	20020422	TR 2001-200103457	20000524
	JP 2003500478	T2	20030107	JP 2000-621345	20000524
	JP 3590592	B2	20041117		
	AU 770786	B2	20040304	AU 2000-45677	20000524
	NZ 515407	A	20040326	NZ 2000-515407	20000524
	RU 2243221	C2	20041227	RU 2001-133458	20000524
	AT 317389	E	20060215	AT 2000-927234	20000524
	ZA 2001009163	A	20030206	ZA 2001-9163	20011106
	NO 2001005700	A	20011122	NO 2001-5700	20011122
	NO 321354	B1	20060502		
	HR 2001000871	A1	20030430	HR 2001-871	20011122
	HK 1046528	A1	20050225	HK 2002-107643	20021022
PRAI	EP 1999-110483	A	19990531		
	WO 2000-EP4701	W	20000524		

OS MARPAT 134:29425

AB The invention discloses pyrimidine derivs. I [R1 = H or halo; R2 = H, halo, lower alkyl or lower alkoxy; R1 and R2 may be together with the two carbon atoms -CH=CH-CH=CH-; R3 = halo, CF3, lower alkyl or lower alkoxy; R4, R6 = (independently) H or lower alkyl; R5 = lower alkyl, lower alkoxy, amino, Ph, hydroxy-lower alkyl, cyano-lower alkyl, carbamoyl-lower alkyl, pyridyl, pyrimidyl, (un)substituted -(CH2)n-piperazinyl, which is optionally substituted by one or two lower alkyl groups or by hydroxy-lower alkyl, -(CH2)n-morpholinyl, -(CH2)n-piperidinyl, -(CH2)n+1-imidazolyl, lower alkyl-sulfanyl, lower alkyl-sulfonyl, benzylamino, -NH-(CH2)n+1N(R7)2, -O-(CH2)n+1-morpholinyl, -O-(CH2)n+1-piperidinyl or -O-(CH2)n+1N(R7)2, wherein R7 = H or lower alkyl; n = 0-2; X = -C(O)N(R7)- or -N(R7)C(O)-] and their pharmaceutically


acceptable acid addition salts as NK-1 receptor antagonists. The preferred compds. exhibited pKi values for NK-1 receptor affinity in the range of 8.00-9.20, e.g., the pKi of II was 8.45. With demonstrated affinity to the NK-1 receptor, these compds. may prove useful for the treatment of medical conditions related to this receptor, e.g., inflammatory conditions such as arthritis, migraine, asthma, etc., and in particular CNS disorders such as depression or emesis.

IT **311339-65-8P 311340-48-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn and biol. activity of phenylpyrimidine derivs. as NK-1 antagonists)


RN 311339-65-8 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-phenyl-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 311340-48-4 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-phenyl-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




IT **311340-89-3**

RL: RCT (Reactant); RACT (Reactant or reagent)  
(prepn and biol. activity of phenylpyrimidine derivs. as NK-1 antagonists)

RN 311340-89-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-phenyl-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)






IT **311340-78-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn and biol. activity of phenylpyrimidine derivs. as NK-1 antagonists)

RN 311340-78-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-phenyl-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:707158 CAPLUS

DN 133:266868

TI Preparation of 4-aryl-2-pyridinyl-1,4-dihydropyrimidine-5-carboxylates for treatment of hepatitis B infection.

IN Stolting, Jorn; Stoltefuss, Jurgen; Goldmann, Siegfried; Kramer, Thomas; Schlemmer, Karl-heinz; Niewohner, Ulrich; Paessens, Arnold; Graef, Erwin; Lottmann, Stefan; Deres, Karl; Weber, Olaf

PA Bayer A.-G., Germany; et al.

SO PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000058302	A1	20001005	WO 2000-EP2327	20000316
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000042891	A5	20001016	AU 2000-42891	20000316
PRAI BS 1999-1161	A	19990325		
WO 2000-EP2327	A	20000316		

OS MARPAT 133:266868

AB Title compds. [I; R1 = (substituted) Ph, furyl, thienyl, triazolyl, pyridyl, cycloalkyl, etc.; R2 = XR12, NR13R14; X = bond, O; R12 = H, alkoxy, carbonyl, (unsatd.) (substituted) (hetero)alkyl; R3 = H, amino, (MeO)2CH, CHO, cyano, CF3, Ph, pyridyl, etc.; R2R3 = OCH2; R4 = H, alkyl, alkenyl, PhCO, acyl; R5 = (substituted) pyridyl], were prepared for treatment of hepatitis B infection (no data). Thus, 3,5-difluoro-2-pyridinecarboximidamide hydrochloride (preparation given), Me 2-acetyl-3-(2-chloro-4-fluorophenyl)-2-propenoate (preparation given), and NH4OAc were refluxed 4 h in Me2CHOH to give 80% Me 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-methyl-1,4-dihydropyrimidine-5-carboxylate.


IT 246872-26-4P 246872-59-3P 298708-48-2P  
 298708-51-7P 298708-53-9P 298708-55-1P  
 298708-57-3P 298708-59-5P 298708-61-9P  
 298708-63-1P 298708-65-3P 298708-67-5P  
 298708-69-7P 298708-71-1P 298708-73-3P  
 298708-75-5P 298708-77-7P 298708-79-9P  
 298708-81-3P 298708-83-5P 298708-85-7P  
 298708-87-9P 298708-89-1P 298708-91-5P  
 298708-93-7P 298708-95-9P 298708-97-1P  
 298708-99-3P 298709-01-0P 298709-03-2P  
 298709-05-4P 298709-07-6P 298709-09-8P  
 298709-10-1P 298709-12-3P 298709-14-5P  
 298709-16-7P 298709-18-9P 298709-20-3P  
 298709-22-5P 298709-23-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-aryl-2-pyridinyl-1,4-dihydropyrimidine-5-carboxylates for treatment of hepatitis B infection)


RN 246872-26-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 246872-59-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-bromo-2-fluorophenyl)-2-(3-chloro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 298708-48-2 CAPLUS

CN Ethanone, 1-[4-(2-chlorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 298708-51-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3-chloro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 298708-53-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3-chloro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 298708-55-1 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-bromophenyl)-2-(3-chloro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 298708-57-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-bromophenyl)-2-(3-chloro-2-pyridinyl)-

1,4-dihydro-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 298708-59-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-chloro-2-nitrophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 298708-61-9 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(3,5-dichlorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 298708-63-1 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-chloro-2-fluoro-5-nitrophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

NAME)




RN 298708-65-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(5-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 298708-67-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-1,4-dihydro-2-(5-methoxy-2-pyridinyl)-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 298708-69-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(5-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 298708-71-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-1,4-dihydro-2-(5-methoxy-2-pyridinyl)-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 298708-73-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-1,4-dihydro-2-(4-methoxy-2-pyridinyl)-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 298708-75-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3-fluoro-4-methoxy-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 298708-77-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 298708-79-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-




pyridinyl)-1,4-dihydro-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 298708-81-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 298708-83-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 298708-85-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester, (-)-(9CI) (CA INDEX NAME)


Rotation (-).



RN 298708-87-9 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3-chloro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester, (-)-(9CI) (CA INDEX NAME)

Rotation (-).




RN 298708-89-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-bromo-2-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 298708-91-5 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-chloro-2-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 298708-93-7 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-bromo-2-fluorophenyl)-2-(3-chloro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 298708-95-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-dichloro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 298708-97-1 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-dichloro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 298708-99-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-chloro-2-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 298709-01-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-4-(2-nitrophenyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 298709-03-2 CAPLUS

CN Ethanone, 1-[4-(2-aminophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 298709-05-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-difluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 298709-07-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-difluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 298709-09-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-difluorophenyl)-6-ethyl-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-, ethyl ester (9CI) (CA INDEX NAME)




RN 298709-10-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-fluoro-4-methylphenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 298709-12-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 6-ethyl-4-(2-fluoro-4-methylphenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-, ethyl ester (9CI) (CA INDEX NAME)




RN 298709-14-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-4-[2-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 298709-16-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 6-ethyl-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-4-[2-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 298709-18-9 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-4-[4-nitro-2-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 298709-20-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 6-ethyl-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-4-[4-nitro-2-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)






RN 298709-22-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-(3-fluoro-2-pyridinyl)-4-[4-fluoro-2-(trifluoromethyl)phenyl]-1,4-dihydro-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 298709-23-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 6-ethyl-4-(2-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 23 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1999:684291 CAPLUS  
 DN 131:299458  
 TI Use of dihydropyrimidines as virucides for hepatitis B  
 IN Stoltefuss, Juergen; Goldmann, Siegfried; Paessens, Arnold; Graef, Erwin;  
 Lottmann, Stefan  
 PA Bayer A.-G., Germany  
 SO Ger. Offen., 78 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19817265	A1	19991021	DE 1998-19817265	19980418
	CA 2328733	AA	19991028	CA 1999-2328733	19990407
	WO 9954312	A1	19991028	WO 1999-EP2346	19990407
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9938134	A1	19991108	AU 1999-38134	19990407
	EP 1073642	A1	20010207	EP 1999-920604	19990407
	EP 1073642	B1	20021023		
	R: DE, ES, FR, GB, IT				
	JP 2002512233	T2	20020423	JP 2000-544651	19990407
	ES 2186354	T3	20030501	ES 1999-920604	19990407
	US 6436943	B1	20020820	US 2000-673581	20001018
PRAI	DE 1998-19817265	A	19980418		
	WO 1999-EP2346	W	19990407		

OS MARPAT 131:299458

AB Dihydropyrimidines I and II [R1 = (un)substituted Ph, furyl, thienyl, triazolyl, pyridyl, cycloalkyl, benzothiazolyl, isoquinolyl; R2 = H, (un)substituted OH, NH2, hydrocarbon, alkoxy carbonyl; R3 = H, NH2, CH(OMe)2, CHO, CN, hydroxyalkylthio, CF3, pyridyl, (un)substituted hydrocarbon, Ph, MeOC6H4; R2R3 = OCH2; R4 = H, alkyl, alkenyl, acyl; R5 = pyridyl, pyrimidinyl, pyrazinyl] were prepared for use in the treatment of hepatitis B (no data). Chus, 2-ClC6H4CHO was treated with MeCOCH2CO2Et and 2-amidinopyridine hydrochloride to give 42% I [R1 = 2-ClC6H4, R2 = OMe, R3 = Me, R4 = H, R5 = 2-pyridyl].


IT 247052-44-4P 247052-45-5P 247052-46-6P  
 247052-47-7P 247052-48-8P 247052-49-9P  
 247052-50-2P 247052-51-3P 247052-52-4P  
 247052-53-5P 247052-54-6P 247052-55-7P  
 247052-56-8P 247052-57-9P 247052-58-0P  
 247052-59-1P 247052-60-4P 247052-61-5P  
 247052-62-6P 247052-63-7P 247052-64-8P  
 247052-65-9P 247052-66-0P 247052-67-1P  
 247052-68-2P 247052-69-3P 247052-70-6P  
 247052-71-7P 247052-72-8P 247052-73-9P  
 247052-74-0P 247052-80-8P 247052-81-9P  
 247052-83-1P 247052-84-2P 247052-85-3P  
 247052-86-4P 247052-87-5P 247052-88-6P

247052-89-7P 247052-90-0P 247052-91-1P  
 247052-92-2P 247052-93-3P 247052-94-4P  
 247052-95-5P 247052-96-6P 247052-97-7P  
 247052-98-8P 247052-99-9P 247053-00-5P  
 247053-01-6P 247053-02-7P 247053-03-8P  
 247053-04-9P 247053-05-0P 247053-06-1P  
 247053-07-2P 247053-08-3P 247053-09-4P  
 247053-10-7P 247053-11-8P 247053-12-9P  
 247053-13-0P 247053-14-1P 247053-15-2P  
 247053-16-3P 247053-17-4P 247053-18-5P  
 247053-19-6P 247053-20-9P 247053-21-0P  
 247053-22-1P 247053-23-2P 247053-24-3P  
 247078-29-1P 247078-30-4P 247078-31-5P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of dihydropyrimidines as virucides for hepatitis B)


RN 247052-44-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 247052-45-5 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-(4-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 247052-46-6 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, 1-methylethyl ester (9CI) (CA INDEX NAME)





RN 247052-50-2 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-chlorophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 247052-51-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-fluorophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 247052-52-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,4-dihydro-6-methyl-4-(3-phenyl-5-quinolinyl)-2-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 247052-53-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,4-dihydro-6-methyl-4-phenyl-2-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 247052-54-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,4-dihydro-4-(2-methoxyphenyl)-6-methyl-2-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 247052-55-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,4-dihydro-6-methyl-4-(2-methylphenyl)-2-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 247052-56-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 247052-57-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-dichlorophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 247052-58-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,4-difluorophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 247052-59-1 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-6-ethyl-1,4-dihydro-2-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 247052-60-4 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 6-(bromomethyl)-4-(2-chlorophenyl)-1,4-dihydro-2-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)






RN 247052-61-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1-acetyl-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 247052-62-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-6-[3-oxo-3-(phenylamino)propyl]-2-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 247052-63-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-6-[3-oxo-3-[(phenylmethyl)amino]propyl]-2-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 247052-64-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-6-[3-oxo-3-(1-phenyl-2-piperidinyl)propyl]-2-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 247052-65-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 6-[3-(butylamino)-3-oxopropyl]-4-(2-chlorophenyl)-1,4-dihydro-2-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 247052-66-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-6-[3-[(2-hydroxyethyl)amino]-3-oxopropyl]-2-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 247052-67-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-6-[3-(4-morpholinyl)-3-oxopropyl]-2-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 247052-68-2 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-6-[3-[(4-hydroxyphenyl)amino]-3-oxopropyl]-2-(2-pyridinyl)-, methyl ester (9CI)  
(CA INDEX NAME)



RN 247052-69-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 6-[3-[(2-aminoethyl)amino]-3-oxopropyl]-4-(2-





RN 247052-73-9 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-cyclohexyl-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 247052-74-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,4-dihydro-6-methyl-2-(2-pyridinyl)-4-(2-thienyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 247052-80-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-6-[3-[(4-hydroxy-2,5-dimethylphenyl)amino]-3-oxopropyl]-2-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 247052-81-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,4-dihydro-6-methyl-4-(2-phenyl-4-benzothiazolyl)-2-(4-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 247052-83-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 247052-84-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-3-thienyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 247052-85-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-3-thienyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 247052-86-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, butyl ester (9CI) (CA INDEX NAME)




RN 247052-87-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, 2-propynyl ester (9CI) (CA INDEX NAME)




RN 247052-88-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-chlorophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, 2-propynyl ester (9CI) (CA INDEX NAME)



RN 247052-89-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, 2-propynyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 247052-90-0 CAPLUS




CN 5-Pyrimidinecarboxylic acid, 4-(4-chlorophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, 2-propynyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 247052-91-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-5-nitrophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 247052-92-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 247052-93-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, 1,1-dimethylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 247052-94-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 247052-95-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-chlorophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 247052-96-6 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, 2-propenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 247052-97-7 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-chlorophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, 2-propenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 247052-98-8 CAPLUS

5-Pyrimidinecarboxylic acid, 6-chloro-4-(2-chlorophenyl)-1,4-dihydro-2-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 247052-99-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-3-pyridinyl)-1,4-dihydro-6-methyl-  
2-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 247053-00-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromo-3-pyridinyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 247053-01-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[2-fluoro-3-(trifluoromethyl)phenyl]-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 247053-02-7 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-[2-fluoro-3-(trifluoromethyl)phenyl]-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 247053-03-8 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-[2-fluoro-3-(trifluoromethyl)phenyl]-1,4-

dihydro-6-methyl-2-(2-pyridinyl)-, methyl ester, monohydrochloride (9CI)  
(CA INDEX NAME)




● HCl

RN 247053-04-9 CAPLUS  
CN 5-Pyrimidinecarboxylic acid, 4-[2,3-bis(trifluoromethoxy)phenyl]-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, methyl ester, monohydrochloride (9CI)  
(CA INDEX NAME)




● HCl

RN 247053-05-0 CAPLUS  
CN 5-Pyrimidinecarboxylic acid, 4-[2,3-bis(trifluoromethoxy)phenyl]-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 247053-06-1 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-[2-fluoro-3-(trifluoromethyl)phenyl]-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 247053-07-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-6-[(2-hydroxyethyl)thio]-2-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 247053-08-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-3-nitrophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 247053-09-4 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-3-nitrophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 247053-10-7 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-3-nitrophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)






● HCl

RN 247053-11-8 CAPLUS  
 CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-3-nitrophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 247053-12-9 CAPLUS  
 CN 5-Pyrimidinecarboxylic acid, 4-[2-[(2-chlorophenyl)thio]phenyl]-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 247053-13-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[2-[(2-chlorophenyl)thio]phenyl]-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 247053-14-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[2-[(2-chlorophenyl)thio]phenyl]-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 247053-15-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[2-[(2-chlorophenyl)thio]phenyl]-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, ethyl ester, monohydrochloride (9CI)


(CA INDEX NAME)



● HCl

RN 247053-16-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(3,4-dichlorophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 247053-17-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(3-chlorophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 247053-18-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,4-dihydro-6-methyl-4-(3-nitrophenyl)-2-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 247053-19-6 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 1,4-dihydro-4-(2-methoxyphenyl)-6-methyl-2-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 247053-20-9 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, 2-cyanoethyl ester (9CI) (CA INDEX NAME)






RN 247053-24-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,4-dihydro-4-(2-hydroxyphenyl)-6-methyl-2-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 247078-29-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, methyl ester, (-)- (9CI) (CA INDEX NAME)




RN 247078-30-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, methyl ester, (+)- (9CI) (CA INDEX NAME)



RN 247078-31-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-1,4-dihydro-6-methyl-2-(2-pyridinyl)-, methyl ester, (-)-(9CI) (CA INDEX NAME)



L4 ANSWER 24 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1999:684290 CAPLUS  
 DN 131:286535  
 TI Preparation of 2-pyridyldihydropyrimidine-5-carboxylates as hepatitis B  
 antiviral agents  
 IN Stoltefuss, Juergen; Goldmann, Siegfried; Paessens, Arnold; Graef, Erwin;  
 Lottmann, Stefan  
 PA Bayer A.-G., Germany  
 SO Ger. Offen., 46 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

*App pti*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19817264	A1	19991021	DE 1998-19817264	19980418
	CA 2328780	AA	19991028	CA 1999-2328780	19990407
	WO 9954326	A1	19991028	WO 1999-EP2344	19990407
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,				
	DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,				
	JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,				
	MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,				
	TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,				
	ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,				
	CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9938133	A1	19991108	AU 1999-38133	19990407
	AU 740318	B2	20011101		
	BR 9909730	A	20001219	BR 1999-9730	19990407
	TR 200003011	T2	20010122	TR 2000-200003011	19990407
	EP 1080086	A1	20010307	EP 1999-920603	19990407
	EP 1080086	B1	20020904		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO				
	JP 2002512243	T2	20020423	JP 2000-544665	19990407
	NZ 507569	A	20020426	NZ 1999-507569	19990407
	AT 223401	E	20020915	AT 1999-920603	19990407
	PT 1080086	T	20021231	PT 1999-920603	19990407
	ES 2183548	T3	20030316	ES 1999-920603	19990407
	CZ 293482	B6	20040512	CZ 2000-3871	19990407
	RU 2245881	C2	20050210	RU 2000-129148	19990407
	TW 548274	B	20030821	TW 1999-88106067	19990416
	ZA 2000005136	A	20010302	ZA 2000-5136	20000926
	BG 104812	A	20010629	BG 2000-104812	20000929
	BG 64649	B1	20051031		
	NO 2000005215	A	20001213	NO 2000-5215	20001017
	US 6696451	B1	20040224	US 2000- <u>673592</u>	20001018
	HK 1039119	A1	20050422	HK 2002-100473	20020121
	US 2004167135	A1	20040826	US 2004- <u>781075</u>	20040217
	NO 2004005259	A	20001213	NO 2004-5259	20041201
PRAI	DE 1998-19817264	A	19980418		
	WO 1999-EP2344	W	19990407		
	US 2000-673592	A1	20001018		

OS MARPAT 131:286535

AB Title compds. [I; R1 = (un)substituted Ph, -furyl, pyridyl, etc.; R2 = H, OH, (di)(alkyl)amino(oxy), hydrocarbyl(oxy), etc.; R3 = CHO, CH(OMe)2, hydrocarbyl, pyridyl, etc.; R4 = H, alk(en)yl, C(=O)Ph, acyl; R5 = (un)substituted pyridyl] were prepared as hepatitis B antiviral agents (no



data). Thus, 2-amidino-3-fluoropyridine (preparation given) was cyclocondensed with MeCOCH<sub>2</sub>CO<sub>2</sub>Et and 2-BrC<sub>6</sub>H<sub>4</sub>CHO to give I (R<sub>1</sub> = C<sub>6</sub>H<sub>4</sub>Br-2, R<sub>2</sub> = OEt, R<sub>3</sub> = Me, R<sub>4</sub> = N, R<sub>5</sub> = 3-fluoro-2-pyridyl).


IT 246872-26-4P 246872-27-5P 246872-28-6P  
 246872-29-7P 246872-30-0P 246872-31-1P  
 246872-32-2P 246872-33-3P 246872-34-4P  
 246872-35-5P 246872-36-6P 246872-37-7P  
 246872-38-8P 246872-39-9P 246872-40-2P  
 246872-41-3P 246872-42-4P 246872-43-5P  
 246872-44-6P 246872-45-7P 246872-46-8P  
 246872-47-9P 246872-48-0P 246872-49-1P  
 246872-50-4P 246872-51-5P 246872-52-6P  
 246872-53-7P 246872-54-8P 246872-55-9P  
 246872-56-0P 246872-58-2P 246872-59-3P  
 246872-60-6P 246872-61-7P 246872-62-8P  
 246872-63-9P 246872-64-0P 246872-65-1P  
 246872-66-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-pyridyldihydropyrimidine-5-carboxylates as hepatitis B antiviral agents)


RN 246872-26-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 246872-27-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-[5-(trifluoromethyl)-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 246872-28-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 246872-29-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 246872-30-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-4-(4-nitrophenyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 246872-31-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-(6-methyl-2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 246872-32-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-chlorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 246872-33-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 6-amino-4-(2-chlorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-, methyl ester (9CI) (CA INDEX NAME)




RN 246872-34-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-4-(3-phenyl-5-quinolinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 246872-35-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 246872-36-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-chlorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 246872-37-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-4-phenyl-, methyl ester (9CI) (CA INDEX NAME)



RN 246872-38-8 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 246872-39-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,6-difluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 246872-40-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-4-[2-(trifluoromethyl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 246872-41-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,6-dichlorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 246872-42-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2,6-dichlorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 246872-43-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 246872-44-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 246872-45-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-2-(3-chloro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 246872-46-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-2-(5-chloro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 246872-47-9 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 246872-48-0 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, 2-phenoxyethyl ester (9CI) (CA INDEX NAME)






RN 246872-49-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-(3-fluoro-2-pyridinyl)-1,4-dihydro-4-(4-iodophenyl)-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 246872-50-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-6-cyclopropyl-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-, methyl ester (9CI) (CA INDEX NAME)




RN 246872-51-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-2-(3-chloro-2-pyridinyl)-  
1,4-dihydro-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 246872-52-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-chloro-3-nitrophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 246872-53-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-bromophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 246872-54-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-bromophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 246872-55-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-bromophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 246872-56-0 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-hydroxyphenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 246872-58-2 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 246872-59-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-bromo-2-fluorophenyl)-2-(3-chloro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 246872-60-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-bromo-2-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 246872-61-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-chloro-2-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 246872-62-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-fluoro-2-methylphenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 246872-63-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-(3-fluoro-2-pyridinyl)-1,4-dihydro-4-(2-iodophenyl)-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 246872-64-0 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-bromo-2-fluorophenyl)-2-(3-chloro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 246872-65-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-fluorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester, (-)-(9CI) (CA INDEX NAME)


Rotation (-).



RN 246872-66-2 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-2-(3-fluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, ethyl ester, (-)-(9CI) (CA INDEX NAME)

Rotation (-).




L4 ANSWER 25 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1999:48708 CAPLUS  
 DN 130:125083  
 TI Preparation of dihydropyrimidinecarboxylates as N-type neuronal calcium channel antagonists.  
 IN Downs, Eileen S.; Michne, William F.; Pierson, M. Edward, Jr.  
 PA Astra Aktiebolag (Publ), Swed.  
 SO PCT Int. Appl., 55 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9901438	A1	19990114	WO 1998-SE1208	19980622
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	ZA 9805323	A	19990111	ZA 1998-5323	19980618
	CA 2294746	AA	19990114	CA 1998-2294746	19980622
	AU 9882499	A1	19990125	AU 1998-82499	19980622
	EP 993450	A1	20000419	EP 1998-932675	19980622
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002508780	T2	20020319	JP 1999-507008	19980622
	US 6218538	B1	20010417	US 1998-171174	19981014
PRAI	SE 1997-2564	A	19970702		
	WO 1998-SE1208	W	19980622		
OS	MARPAT 130:125083				
AB	Title compds. [I; R1 = (substituted) (hetero)aryl; R2 = (unsatd.) alkyl substituted by Ph, heteroaryl; R3 = mono- or bicyclic (substituted) (hetero)aryl; R4, R5 = H, alkyl, PhCH2; NR4R5 = piperidinyl, morpholinyl, 3,4-dehydropiperidinyl, thiomorpholinyl, perhydroazepinyl, pyrrolidinyl, (substituted) piperazinyl; X = O, S, NR6; R6 = H, alkyl; n = 2-4], were prepared for treatment of, e.g., cerebrovascular ischemia and pain (no data). Thus, 4-[2-(1-piperidinyl)ethoxy]acetoacetate (preparation given), 3,4-dichlorobenzaldehyde, and 2-amidinothiophene hydrochloride (preparation given) were stirred with NaHCO3 in DMF at 60° for 4 days to give 3-phenylpropyl 4-(3,4-dichlorophenyl)-6-[[2-(1-piperidinyl)ethoxy]methyl]-2-(2-thienyl)-1,4-dihydropyrimidine-5-carboxylate.				
IT	<b>219795-96-7P 219795-97-8P</b> RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of dihydropyrimidinecarboxylates as N-type neuronal calcium channel antagonists)				
RN	219795-96-7 CAPLUS				
CN	5-Pyrimidinecarboxylic acid, 4-(3,4-dichlorophenyl)-1,4-dihydro-6-[[2-(1-piperidinyl)ethoxy]methyl]-2-(4-pyridinyl)-, 3-phenylpropyl ester (9CI) (CA INDEX NAME)				



RN 219795-97-8 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(3,4-dichlorophenyl)-1,4-dihydro-6-[[2-(1-piperidinyl)ethoxy)methyl]-2-(2-pyridinyl)-, 3-phenylpropyl ester (9CI)  
(CA INDEX NAME)




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L4 ANSWER 26 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1996:229176 CAPLUS  
 DN 125:33447  
 TI Synthesis and reactions of 3'-azanifedipine  
 AU Goerlitzer, K.; Ewert, H.-J.  
 CS Inst. Pharmazeutische Chem., Technischen Univ. Braunschweig, Germany  
 SO Pharmazie (1996), 51(4), 207-12  
 CODEN: PHARAT; ISSN: 0031-7144  
 PB Govi-Verlag Pharmazeutischer Verlag  
 DT Journal  
 LA German  
 AB Nicotinaldehydes reacted with Me acetoacetate and NH<sub>3</sub> to yield the dihydropyridines (DHP) I (R = Cl, NO<sub>2</sub>; R<sub>1</sub>, R<sub>4</sub> = H; R<sub>2</sub>R<sub>3</sub> = bond), the isomeric 1,2-DHP II (R<sub>1</sub>, R<sub>2</sub> = H) and the tetrahydropyrimidines (THPM) III. The corresponding heteroaroms. were obtained by cerium(IV)-oxidation. Reduction of the NO<sub>2</sub> group in the bipyridines I (R = NO<sub>2</sub>; R<sub>1</sub>R<sub>2</sub>, R<sub>3</sub>R<sub>4</sub> = bond) and II (R = NO<sub>2</sub>, R<sub>1</sub>R<sub>2</sub> = bond) with Zn/NH<sub>4</sub>Cl leads to the cyclic hydroxamic acids, while with SnCl<sub>2</sub>/HCl the lactames are isolated. Irradiation of I (R = NO<sub>2</sub>; R<sub>1</sub>, R<sub>4</sub> = H; R<sub>2</sub>R<sub>3</sub> = bond) with UV-A light yields the nitroso bipyridine. The latter cyclizes to form the hydroxamic acid when treated with HCl. Subsequent reduction with PCl<sub>3</sub> gave the lactam. The half wave potentials of the DHP and THPM were determined by anodic oxidation by difference pulse voltammetry with nifedipine as reference  
 IT **177857-69-1P 177857-70-4P**  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and reactions of 3'-azanifedipine)  
 RN 177857-69-1 CAPLUS  
 CN 5-Pyrimidinecarboxylic acid, 4-methyl-2,6-bis(2-nitro-3-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 177857-70-4 CAPLUS  
 CN 5-Pyrimidinecarboxylic acid, 2,4-bis(2-chloro-3-pyridinyl)-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 27 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1993:169117 CAPLUS  
 DN 118:169117  
 TI Preparation of 4-(imidazolin-5-on-2-yl)pyrimidine-5-carboxylates as herbicides.  
 IN Seitz, Thomas; Luerksen, Klaus; Santel, Hans Joachim; Schmidt, Robert R.  
 PA Bayer A.-G., Germany  
 SO Eur. Pat. Appl., 50 pp.  
 CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 517052	A1	19921209	EP 1992-108733	19920523
	R: BE, CH, DE, DK, ES, FR, GB, IT, LI, NL				
	DE 4118720	A1	19921210	DE 1991-4118720	19910607
	US 5244865	A	19930914	US 1992-891493	19920529
	AU 9217326	A1	19921210	AU 1992-17326	19920601
	JP 05194493	A2	19930803	JP 1992-165303	19920601
	BR 9202151	A	19930126	BR 1992-2151	19920605
	ZA 9204101	A	19930224	ZA 1992-4101	19920605
	CA 2070717	AA	19921208	CA 1992-2070717	19920608
PRAI	DE 1991-4118720	A	19910607		
OS	MARPAT 118:169117				

AB Title compds. [I; R1 = H, halo, cyano, NO<sub>2</sub>, SCN, (substituted) OH, SH, amino, CO, SO, SO<sub>2</sub>, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl; R2 = H, OH, halo, (halo)alkyl; R3 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, cation; R4, R5 = H, (halo)alkyl, cycloalkyl; X = O, S], were prepared as herbicides (no data). Thus, di-Et  $\alpha$ -methylpyrimidin-4,5-dicarboxylate was heated with H<sub>2</sub>NCOCMe(NH<sub>2</sub>)CHMe<sub>2</sub> and KOCMe<sub>3</sub> in PhMe at 80° for 16 h to give title compound II. II was said to show superior herbicidal activity/crop plant tolerance both pre- and postemergent.

IT **146380-65-6P 146380-67-8P 146381-18-2P**


**146381-19-3P 146381-20-6P 146381-21-7P**

**146381-22-8P 146381-23-9P 146381-24-0P**

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as herbicide)


RN 146380-65-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[4,5-dihydro-4-methyl-4-(1-methylethyl)-5-oxo-1H-imidazol-2-yl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 146380-67-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[4,5-dihydro-4-methyl-4-(1-methylethyl)-5-oxo-1H-imidazol-2-yl]-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 146381-18-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[4,5-dihydro-4-methyl-4-(1-methylethyl)-5-oxo-1H-imidazol-2-yl]-2-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 146381-19-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[4,5-dihydro-4-methyl-4-(1-methylethyl)-5-oxo-1H-imidazol-2-yl]-2-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 146381-20-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[4,5-dihydro-4-methyl-4-(1-methylethyl)-5-oxo-1H-imidazol-2-yl]-2-(2-pyridinyl)-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 146381-21-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[4,5-dihydro-4-methyl-4-(1-methylethyl)-5-oxo-1H-imidazol-2-yl]-2-(2-pyridinyl)-, 2-propynyl ester (9CI) (CA INDEX NAME)




RN 146381-22-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[4,5-dihydro-4-methyl-4-(1-methylethyl)-5-oxo-1H-imidazol-2-yl]-2-(3-pyridinyl)-, propyl ester (9CI) (CA INDEX NAME)




RN 146381-23-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[4,5-dihydro-4-methyl-4-(1-methylethyl)-5-oxo-1H-imidazol-2-yl]-2-(3-pyridinyl)-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 146381-24-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[4,5-dihydro-4-methyl-4-(1-methylethyl)-5-oxo-1H-imidazol-2-yl]-2-(3-pyridinyl)-, 2-propynyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 28 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1993:147531 CAPLUS

DN 118:147531

TI Studies on cerebral protective agents. II. Novel 4-arylpyrimidine derivatives with anti-anoxic and anti-lipid peroxidation activities (2)

AU Kuno, Atsushi; Sugiyama, Yoshie; Katsuta, Kiyotaka; Sakai, Hiroyoshi; Takasugi, Hisashi

CS New Drug Res. Lab., Fujisawa Pharm. Co., Ltd., Osaka, 532, Japan

SO Chemical & Pharmaceutical Bulletin (1992), 40(9), 2423-31

CODEN: CPBTAL; ISSN: 0009-2363

DT Journal

LA English

AB In a search for new cerebral protective agents with anti-anoxic (AA) and anti-lipid peroxidn. (ALP) activities, a series of 4-arylpyrimidines, I [R = CONHCH<sub>2</sub>NMe<sub>2</sub>, CONH(CH<sub>2</sub>)<sub>2</sub>NMe<sub>2</sub>, CONH(CH<sub>2</sub>)<sub>2</sub>NEt<sub>2</sub>, CONH(CH<sub>2</sub>)<sub>3</sub>NMe<sub>2</sub>, R<sub>3</sub> = Me, Et, CF<sub>3</sub>, N, R<sub>4</sub> = Ph, X = 3-, 4-NO<sub>2</sub>; R = CONR<sub>1</sub>R<sub>2</sub>, NR<sub>1</sub>R<sub>2</sub> = NH(CH<sub>2</sub>)<sub>2</sub>OH, 1-piperazinyl, NHCH<sub>2</sub>CH<sub>2</sub>NMeCH<sub>2</sub>Ph, etc., R<sub>3</sub> = Me, R<sub>4</sub> = Ph, X = 3-NO<sub>2</sub>; R = COR<sub>5</sub>, R<sub>3</sub> = Me, Et, H, CF<sub>3</sub>, R<sub>4</sub> = Ph, 4-ClC<sub>6</sub>H<sub>4</sub>, 4-MeOC<sub>6</sub>H<sub>4</sub>, etc., R<sub>5</sub> = 4-methyl-1-piperazinyl, X = 2-, 3-, 4-NO<sub>2</sub>, 3-cyano, 3-Cl], bearing an amino moiety in the C-5 position of the pyrimidine nucleus, was synthesized and tested for AA and ALP activities. Thus, I (R = CO<sub>2</sub>H, R<sub>3</sub> = Me, CF<sub>3</sub>, H, Et, R<sub>4</sub> = Ph, 4-ClC<sub>6</sub>H<sub>4</sub>, X = 3-, 4-NO<sub>2</sub>) (II) were treated with amines to give the corresponding amides. II were prepared in several steps from R<sub>3</sub>COCH<sub>2</sub>CO<sub>2</sub>R and 3- and 4-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>CHO. Among the prepared compds., I (R = CONR<sub>1</sub>R<sub>2</sub>, NR<sub>1</sub>R<sub>2</sub> = 4-methyl-1-piperazinyl, R<sub>3</sub> = Me, R<sub>4</sub> = Ph, X = 3-NO<sub>2</sub>) was most effective on both assays and on arachidonate-induced cerebral edema in rats. Structure-activity relationships in regard to AA activity of this series of compds. are also discussed.


IT 103312-16-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation, anti-anoxia, and lipid peroxidn. activity of)

RN 103312-16-9 CAPLUS

CN Piperazine, 1-methyl-4-[[4-methyl-6-(3-nitrophenyl)-2-(4-pyridinyl)-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 29 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1991:583341 CAPLUS  
 DN 115:183341  
 TI Preparation of substituted 2,4-diarylpyrimidines as herbicides  
 IN Prisbylla, Michael P.  
 PA ICI Americas, Inc., USA  
 SO U.S., 14 pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5022915	A	19910611	US 1990-487334	19900301
PRAI	US 1990-487334		19900301		
OS	MARPAT 115:183341				


AB Title compds. (I; R = Q1-Q4; R1, R2 = H, Br, Cl, F, cyano, CF3, OCF3; R3 = H, alkyl, CO2Me, CO2Et, CH2Cl, CH2OMe, CH:CH2, alkylthio, alkoxy; R4 = H, OH, alkyl, alkylthio, alkoxy; R5 = H, F), were prepared Thus, 1-(3-trifluoromethylphenyl)-2-(N,N-dimethylaminomethylene)-1-butanone, benzamidinium hydrochloride, and Na2CO3 were refluxed 6 h in EtOH to give 40% title compound I (R = Ph, R3 = Et, R4 = R5 = H). I at 4 lb/acre preemergent gave 70-100% control of grasses.

IT 136433-01-7P 136433-12-0P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as herbicide)


RN 136433-01-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-(4-pyridinyl)-4-[3-(trifluoromethyl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 136433-12-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-(4-pyridinyl)-4-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)





L4 ANSWER 30 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1986:572492 CAPLUS

DN 105:172492

TI Pyrimidine derivatives

IN Takaya, Takao; Takasugi, Hisashi; Kuno, Atsushi; Sugiyama, Yoshie

PA Fujisawa Pharmaceutical Co., Ltd. , Japan

SO Eur. Pat. Appl., 192 pp.

CODEN: EPXXDW


DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 169712	A2	19860129	EP 1985-305143	19850718
	EP 169712	A3	19861203		
	EP 169712	B1	19901212		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LJ, NL, SE				
	US 4698340	A	19871006	US 1985-753912	19850711
	ZA 8505369	A	19860625	ZA 1985-5369	19850716
	FI 8502796	A	19860120	FI 1985-2796	19850717
	DK 8503279	A	19860120	DK 1985-3279	19850718
	NO 8502869	A	19860120	NO 1985-2869	19850718
	ES 545347	A1	19861016	ES 1985-545347	19850718
	AT 59034	E	19901215	AT 1985-305143	19850718
	AU 8545202	A1	19860123	AU 1985-45202	19850719
	JP 61040272	A2	19860226	JP 1985-160784	19850719
	JP 06049688	B4	19940629		
	US 4727073	A	19880223	US 1985-779043	19850923
	ZA 8507359	A	19860528	ZA 1985-7359	19850924
	FI 8503698	A	19860402	FI 1985-3698	19850926
	EP 177287	A2	19860409	EP 1985-306880	19850927
	EP 177287	A3	19861126		
	EP 177287	B1	19901205		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	AT 58897	E	19901215	AT 1985-306880	19850927
	DK 8504436	A	19860402	DK 1985-4436	19850930
	NO 8503853	A	19860402	NO 1985-3853	19850930
	ES 547419	A1	19870316	ES 1985-547419	19850930
	AU 8548143	A1	19860410	AU 1985-48143	19851001
	JP 61087669	A2	19860506	JP 1985-219010	19851001
PRAI	GB 1984-18380	A	19840719		
	GB 1984-24711	A	19841001		
	GB 1985-9623	A	19850415		
	GB 1985-9633	A	19850415		
	EP 1985-305143	A	19850718		
	EP 1985-306880	A	19850927		
OS	MARPAT 105:172492				
AB	Pyrimidines I (R = substituted aryl; R1 = CO2H, esterified CO2H, alkanoyl, etc.; R2 = H, aryl, alkyl, etc.; R3 = alkyl, aryl) were prepared, and they showed their usefulness in the treatment of cerebrovascular diseases. Dihydropyrimidine derivative II was heated with MnO2 to give I (R = 4-pyridyl, R1 = CO2Et, R2 = Me, R3 = Ph). II was prepared from an $\alpha$ -(arylmethylene)acetoacetate ester and an amidine.				
IT	<b>103293-18-1P 103293-25-0P</b>				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(preparation and reaction of)				
RN	103293-18-1 CAPLUS				

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-5-nitrophenyl)-1,4-dihydro-6-methyl-2-(3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 103293-25-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,4-dihydro-6-methyl-4-(3-nitrophenyl)-2-(4-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)



IT 103294-05-9P 103294-37-7P 103294-38-8P

103311-88-2P 103311-90-6P 103312-08-9P

103312-12-5P 103312-15-8P 103312-16-9P


103312-18-1P 103312-19-2P 103312-24-9P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, for treatment of cerebrovascular disease)


RN 103294-05-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-methyl-6-(3-nitrophenyl)-2-(3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 103294-37-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-nitrophenyl)-2-(4-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 103294-38-8 CAPLUS

CN Ethanone, 1-(2,4-di-4-pyridinyl-5-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 103311-88-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-5-nitrophenyl)-6-methyl-2-(3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 103311-90-6 CAPLUS


CN Pyridinium, 3-[5-(ethoxycarbonyl)-4-methyl-6-[2-(methylthio)-5-nitrophenyl]-2-pyrimidinyl]-1-methyl-, iodide (9CI) (CA INDEX NAME)



● I<sup>-</sup>


RN 103312-08-9 CAPLUS

CN Piperazine, 1-methyl-4-[[4-methyl-6-(4-nitrophenyl)-2-(4-pyridinyl)-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 103312-12-5 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-(dimethylamino)ethyl]-4-methyl-6-(4-nitrophenyl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 103312-15-8 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-(dimethylamino)ethyl]-4-methyl-6-(3-nitrophenyl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 103312-16-9 CAPLUS


CN Piperazine, 1-methyl-4-[[4-methyl-6-(3-nitrophenyl)-2-(4-pyridinyl)-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 103312-18-1 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-methyl-6-(3-nitrophenyl)-2-(4-pyridinyl)-  
(9CI) (CA INDEX NAME)

RN 103312-19-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-methyl-6-(4-nitrophenyl)-2-(4-pyridinyl)-  
(9CI) (CA INDEX NAME)

RN 103312-24-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-methyl-6-[2-(methylthio)-5-nitrophenyl]-2-(3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 31 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1984:455110 CAPLUS  
 DN 101:55110  
 TI Dihydropyrimidines useful in treating circulatory ailments  
 IN Stoltefuss, Juergen; Boeshagen, Horst; Schramm, Matthias; Thomas, Guenter  
 PA Bayer A.-G. , Fed. Rep. Ger.  
 SO Ger. Offen., 40 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3234684	A1	19840322	DE 1982-3234684	19820918
	US 4822798	A	19890418	US 1983-526931	19830826
	EP 103796	A2	19840328	EP 1983-108692	19830903
	EP 103796	A3	19850703		
	EP 103796	B1	19871111		
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
	AT 30720	E	19871115	AT 1983-108692	19830903
	JP 59073572	A2	19840425	JP 1983-168503	19830914
	JP 06013484	B4	19940223		
	ES 525692	A1	19850401	ES 1983-525692	19830916
	CA 1250575	A1	19890228	CA 1983-436914	19830916
PRAI	DE 1982-3234684	A	19820918		
	EP 1983-108692	A	19830903		

OS CASREACT 101:55110


AB Antihypertensive and coronary vasodilating (no data)  
 dihydropyrimidinecarboxylates I [R = (un)substituted Ph; R2 =  
 (un)substituted, (un)saturated aliphatic, aromatic, heterocyclyl; R1,R3 =  
 H,R2] were  
 prepared Thus, PhC(:NH)NH2.HCl was cyclocondensed with 2-  
 O2NC6H4CH:C(COMe)CO2Et by refluxing in EtOH with NaOAc to give 55.71% I (R  
 = 2-O2NC6H4, R1 = Et, R2 = Me, R3 = Ph).

IT **90961-40-3P 90961-41-4P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)

RN 90961-40-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-(4-  
 pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 90961-41-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-(2-  
 pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)

10/781,075



10/781,075

=> => d his

(FILE 'HOME' ENTERED AT 12:52:56 ON 12 JUN 2006)

FILE 'REGISTRY' ENTERED AT 12:53:05 ON 12 JUN 2006

L1 STRUCTURE UPLOADED

L2 4 S L1 SSS SAM

L3 597 S L1 SSS FUL

FILE 'CAPLUS' ENTERED AT 12:54:08 ON 12 JUN 2006

L4 31 S L3

FILE 'CAOLD' ENTERED AT 12:55:07 ON 12 JUN 2006

=> s l3

L5 0 L3

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.44

327.36

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-23.25

STN INTERNATIONAL LOGOFF AT 12:55:18 ON 12 JUN 2006